{"gene":"GDF15","run_date":"2026-04-28T18:06:52","timeline":{"discoveries":[{"year":1997,"finding":"GDF15 (then called MIC-1) is a divergent member of the TGF-β superfamily. It is synthesized as a propeptide, undergoes proteolytic cleavage, and is secreted as a cysteine-rich disulfide-linked 25 kDa dimer. In macrophages, its expression is upregulated by IL-1β, TNF-α, IL-2, M-CSF, and TGF-β, and purified recombinant MIC-1 inhibits LPS-induced macrophage TNF-α production, indicating an autocrine regulatory role in limiting macrophage activation.","method":"Subtraction cloning, CHO-cell expression with propeptide cleavage verification, purification of recombinant protein, functional TNF-α inhibition assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning paper with biochemical characterization, expression studies, and direct functional assay; foundational study replicated across the field","pmids":["9326641"],"is_preprint":false},{"year":2000,"finding":"GDF15 (PTGF-β) is a direct transcriptional target of p53; the GDF15 promoter contains two p53-binding site motifs, one of which is essential for p53-mediated induction and specifically binds recombinant p53 in gel-shift assays. GDF15 overexpression induces both G1 cell-cycle arrest and apoptosis in breast cancer cells, establishing it as a downstream mediator of p53-dependent growth arrest.","method":"Promoter-luciferase reporter assay, electrophoretic mobility shift assay (EMSA) with recombinant p53, adenoviral overexpression, flow cytometry for cell-cycle and apoptosis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding of p53 to GDF15 promoter shown by EMSA, functional consequence confirmed by adenoviral overexpression with defined phenotype","pmids":["10777512"],"is_preprint":false},{"year":2001,"finding":"GDF15 (NAG-1) expression is induced by NSAID treatment (cyclooxygenase inhibitors) through COX-independent mechanisms in colorectal cancer cells, and forced GDF15 overexpression increases basal apoptosis and reduces tumorigenicity in nude mice, demonstrating a proapoptotic and antitumorigenic function.","method":"Subtractive hybridization, stable transfection, soft-agar colony assay, xenograft tumor model in nude mice","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (transfection, in vitro growth assay, in vivo xenograft) supporting antitumorigenic function","pmids":["11259636"],"is_preprint":false},{"year":2006,"finding":"GDF15 is induced in cardiomyocytes under ischemia/reperfusion (I/R) via NO-peroxynitrite-dependent signaling. Gdf15-knockout mice develop larger infarct sizes and more cardiomyocyte apoptosis after I/R than wild-type littermates. Recombinant GDF15 protects cultured cardiomyocytes from apoptosis during simulated I/R, and this protective effect is abolished by PI3K inhibitors and dominant-negative Akt1, placing GDF15 upstream of PI3K-Akt1 survival signaling.","method":"Gdf15 gene-targeted (knockout) mice with coronary artery ligation model, recombinant GDF15 treatment, histone ELISA/TUNEL/annexin-V FACS for apoptosis, PI3K inhibitor pharmacology, adenoviral dominant-negative Akt1","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO model with defined phenotype plus pharmacological and dominant-negative mechanistic dissection, replicated with recombinant protein","pmids":["16397141"],"is_preprint":false},{"year":2007,"finding":"Elevated circulating MIC-1/GDF15 produced by tumors causes anorexia and weight loss by acting centrally; in xenograft models, antibody neutralization of MIC-1 reverses weight loss. GDF15 mediates its effects via hypothalamic TGF-β receptor II, and downstream activation of ERK1/2, STAT3, and modulation of NPY and POMC neuropeptides.","method":"Prostate cancer xenograft mouse model, anti-MIC-1 antibody neutralization, hypothalamic signaling analysis (ERK1/2, STAT3), neuropeptide measurement","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — antibody neutralization reversal in vivo combined with defined downstream signaling pathway identification; replicated across multiple cancer models","pmids":["17982462"],"is_preprint":false},{"year":2007,"finding":"During erythroblast maturation, GDF15 expression and secretion increase substantially. In β-thalassemia patients, markedly elevated serum GDF15 suppresses hepcidin mRNA expression in primary human hepatocytes; depletion of GDF15 from thalassemia patient serum reverses hepcidin suppression, demonstrating that GDF15 is a key erythroid regulator that suppresses hepcidin and contributes to iron overload.","method":"Erythroblast transcriptome profiling, GDF15 ELISA in patient serum, primary hepatocyte culture with patient serum, GDF15 immunodepletion with functional rescue","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — immunodepletion experiment directly demonstrates GDF15 causality for hepcidin suppression; supported by large patient cohort and primary cell assays","pmids":["17721544"],"is_preprint":false},{"year":2014,"finding":"In transgenic mice ubiquitously expressing human GDF15 (NAG-1), GDF15 prevents obesity by increasing expression of thermogenic genes (UCP1, PGC1α, Dio2, Cox8b) in brown adipose tissue and lipolytic genes (Adrb3, ATGL, HSL) in both white and brown adipose tissue, leading to higher energy expenditure without reducing food intake.","method":"Transgenic mouse model, xenograft model (melanoma cells secreting GDF15), thermogenic and lipolytic gene expression analysis, metabolic phenotyping (glucose tolerance, insulin levels, energy expenditure)","journal":"International journal of obesity","confidence":"High","confidence_rationale":"Tier 2 — transgenic and xenograft models with detailed mechanistic gene expression analysis; consistent results across two experimental approaches","pmids":["24531647"],"is_preprint":false},{"year":2016,"finding":"GDF15 produced in skeletal muscle with mitochondrial dysfunction (due to Crif1 deficiency activating UPRmt) acts as a myomitokine to regulate systemic energy homeostasis; elevated GDF15 secretion in muscle-specific Crif1-KO mice protects against obesity and improves insulin sensitivity. Recombinant GDF15 in ob/ob mice reduces body weight through elevated oxidative metabolism and lipid mobilization in liver, muscle, and adipose tissue.","method":"Muscle-specific Crif1-KO mouse model, recombinant GDF15 administration in ob/ob mice, metabolic phenotyping, oxidative metabolism assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic muscle-specific KO with defined metabolic phenotype, corroborated by recombinant GDF15 treatment experiments","pmids":["27986797"],"is_preprint":false},{"year":2017,"finding":"GFRAL (GDNF family receptor α-like) is the cognate receptor for GDF15 in the hindbrain. GDF15 binds GFRAL with high affinity; Gfral-knockout mice are refractory to GDF15-induced reductions in food intake, body weight, and glucose parameters. GFRAL mRNA is expressed exclusively in neurons of the area postrema and nucleus of the solitary tract. GDF15-induced cell signaling requires interaction of GFRAL with the co-receptor RET tyrosine kinase.","method":"Receptor binding assay (high-affinity binding), Gfral-knockout mice with recombinant GDF15 treatment, GFRAL monoclonal antibody blockade in rats, immunohistochemistry/in situ hybridization for receptor localization, RET co-receptor signaling studies","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1-2 — multiple independent groups simultaneously identified GFRAL using binding assays, genetic KO, and antibody blockade; findings replicated across four independent papers in the same issue","pmids":["28846097","28846098","28953886","28846099"],"is_preprint":false},{"year":2017,"finding":"GDF15 activates GFRAL-expressing neurons exclusively in the area postrema and nucleus tractus solitarius of the brainstem, which then activate neurons in the parabrachial nucleus and central amygdala (the 'emergency circuit'). Gfral-knockout mice are hyperphagic under stress conditions and resistant to chemotherapy-induced anorexia and weight loss, establishing this as a non-homeostatic neural circuit.","method":"Gfral-knockout mouse model with chemotherapy-induced anorexia model, neuronal activation mapping (c-Fos), circuit tracing, metabolic phenotyping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined behavioral and circuit-level phenotype using multiple stress paradigms","pmids":["28953886"],"is_preprint":false},{"year":2018,"finding":"GDF15 promotes proliferation of cervical cancer cells by binding to ErbB2 (HER2) in a protein complex, leading to phosphorylation of AKT1 and Erk1/2 and upregulation of CyclinD1 and CyclinE1 while downregulating p21. C-myc trans-activates GDF15 expression by binding E-box motifs in the GDF15 promoter, creating a positive feedback loop.","method":"Immunoprecipitation to show GDF15-ErbB2 complex, western blotting for phospho-AKT1 and phospho-Erk1/2, chromatin immunoprecipitation (ChIP) for C-myc binding to GDF15 promoter, flow cytometry for cell cycle, xenograft tumor formation assay","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP and ChIP provide mechanistic evidence but ErbB2 as a GDF15 receptor is a single-lab finding not widely replicated","pmids":["29636108"],"is_preprint":false},{"year":2019,"finding":"ARRB1 (β-Arrestin1) interacts directly with pro-GDF15 and facilitates its transport to the Golgi apparatus for proteolytic cleavage and maturation into secreted GDF15. Arrb1-deficient mice have impaired GDF15 maturation and develop accelerated steatohepatitis; re-expression of Arrb1 or supplementation with recombinant GDF15 rescues the phenotype.","method":"Co-immunoprecipitation of ARRB1 with pro-GDF15, Arrb1-knockout mouse models (HFD and MCD diet), recombinant GDF15 rescue experiment, subcellular fractionation/Golgi localization","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus KO rescue provides mechanistic evidence; Golgi transport role supported by genetic and biochemical data from single lab","pmids":["31857195"],"is_preprint":false},{"year":2019,"finding":"Metformin induces GDF15 expression and secretion from hepatocytes by activating ATF4 and CHOP (DDIT3) transcription factors as part of the integrated stress response. In wild-type mice on high-fat diet, oral metformin increases serum GDF15 and reduces food intake and body mass; these effects are absent in GDF15-null mice, demonstrating that GDF15 is required for metformin's effects on appetite and body weight.","method":"Unbiased hepatocyte transcriptomics, human serum proteomics, primary mouse hepatocyte culture, GDF15-null mice with metformin treatment, ATF4/CHOP mechanistic studies","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — GDF15-null genetic model with defined phenotype plus mechanistic transcription factor identification in primary cells","pmids":["32694673"],"is_preprint":false},{"year":2019,"finding":"GDF15 expression is regulated by the integrated stress response (ISR) in selected tissues during sustained high-fat feeding or dietary amino acid imbalance. Pharmacological GDF15 administration to mice triggers conditioned taste aversion, suggesting that GDF15 induces aversive/nausea-like responses rather than classical satiety signaling.","method":"Mouse dietary stress models (high-fat and amino acid imbalance diets), ISR pathway analysis in tissues, conditioned taste aversion behavioral assay","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple dietary models with ISR pathway analysis plus defined behavioral phenotype (conditioned taste aversion) establishing mechanistic basis","pmids":["30639358"],"is_preprint":false},{"year":2019,"finding":"GDF15 mediates the weight loss effects of metformin in vivo; in two independent randomized controlled clinical trials, metformin increases circulating GDF15. In mice, GDF15 is expressed predominantly in the distal intestine and kidney in response to metformin, and Gdf15-knockout or GFRAL-antagonist antibody-treated mice fail to show metformin-induced body-weight reduction, while glucose-lowering effects are preserved.","method":"Randomized controlled clinical trials (two independent), Gdf15-knockout mice, GFRAL antagonist antibody in obese mice, tissue-specific GDF15 expression analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — two RCTs plus genetic KO and pharmacological antagonism converge on the same mechanism; GDF15-independent glucose lowering also established","pmids":["31875646"],"is_preprint":false},{"year":2019,"finding":"Brown adipocytes release GDF15 in response to thermogenic activation via norepinephrine/cAMP through protein kinase A (PKA)-mediated mechanisms, and this release requires the active FGF21-β-klotho signaling pathway. GDF15 released by brown adipocytes targets macrophages and downregulates proinflammatory gene expression.","method":"Cold exposure of mice, norepinephrine/cAMP treatment of brown adipocyte cultures, PKA inhibitor experiments, FGF21/β-klotho invalidation cell models, RAW264.7 macrophage co-culture/conditioned medium experiments","journal":"Obesity (Silver Spring)","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vitro mechanistic dissection with PKA and FGF21 pathway validated, anti-inflammatory targeting of macrophages shown, single lab","pmids":["31411815"],"is_preprint":false},{"year":2020,"finding":"Antibody-mediated inhibition of GFRAL (monoclonal antibody 3P10) blocks GDF15-driven RET co-receptor recruitment and signaling on brainstem neurons. GDF15-GFRAL-RET pathway activation induces lipid oxidation genes in adipose tissue, and peripheral sympathetic nervous system and adipose triglyceride lipase (ATGL) are required for GDF15-induced lipolysis and adipose/muscle mass loss, establishing a peripheral sympathetic-lipolytic axis downstream of GFRAL-RET.","method":"GFRAL antagonist monoclonal antibody (3P10) in tumor-bearing mice, chemical sympathectomy, ATGL-knockout mice, adipose tissue gene expression analysis, cancer cachexia mouse models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological approaches identifying sympathetic axis and ATGL as mediators of GDF15-induced peripheral lipolysis","pmids":["32661391"],"is_preprint":false},{"year":2020,"finding":"GDF15 promotes immunosuppression in hepatocellular carcinoma by interacting with CD48 on T cells (identified as a GDF15 receptor in the immune system). This interaction downregulates STUB1, an E3 ubiquitin ligase that mediates FOXP3 degradation, thereby stabilizing FOXP3 and enhancing generation and suppressive function of regulatory T cells.","method":"Co-immunoprecipitation of GDF15 with CD48, mass spectrometry, CyTOF immune profiling, Gdf15-knockout mouse orthotopic HCC models, RNA sequencing, ChIP, OT-I transgenic mice, flow cytometry for FOXP3 and Treg function","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and MS identify CD48 interaction, STUB1/FOXP3 mechanism supported by multiple methods, but CD48 as GDF15 receptor is a single-lab finding requiring independent replication","pmids":["34489334"],"is_preprint":false},{"year":2020,"finding":"GDF15 induces visceral malaise (conditioned taste aversion, kaolin intake) but does not reduce feeding motivation or amplify gastrointestinal satiation signals (CCK or ingested food), in contrast to semaglutide. GDF15 does not modulate AgRP neuron calcium signaling, while semaglutide does; the two agents act through largely distinct, additive neural mechanisms to reduce food intake.","method":"Rat pharmaco-behavioral experiments (CCK potentiation, progressive ratio operant paradigm, kaolin intake, conditioned affective food aversion), fibre photometry in AgRP-Cre mice","journal":"Diabetes, obesity & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal behavioral and photometry methods dissecting GDF15 mechanism vs. GLP-1 agonist, single lab","pmids":["35129264"],"is_preprint":false},{"year":2020,"finding":"CRP induces GDF15 transcription in human aortic endothelial cells via p53 recruitment to two p53-binding sites in the GDF15 promoter, as confirmed by ChIP and dual-luciferase reporter assays, linking inflammatory CRP signaling to p53-dependent GDF15 expression.","method":"CRP treatment of human aortic endothelial cells, dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) for p53 at GDF15 promoter","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — direct mechanistic evidence (ChIP + reporter) for CRP-p53-GDF15 axis in primary endothelial cells, single lab","pmids":["29967567"],"is_preprint":false},{"year":2021,"finding":"AMPK (specifically β1-containing complexes) mediates energetic stress-induced hepatic GDF15 expression. Direct AMPK β1 activation (A769662) increases hepatic Gdf15 expression and circulating GDF15 independently of ER stress. Effects of AICAR, R419, and A769662 on GDF15 are all attenuated in AMPKβ1-knockout mice, while CHOP (downstream of ER stress) is not required for A769662-induced GDF15.","method":"AMPKβ1-knockout and CHOP-knockout mice, three pharmacological AMPK activators (AICAR, R419, A769662), hepatic adenine nucleotide and GDF15 measurements, food intake assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — three distinct AMPK activators plus two genetic KO models with orthogonal results dissecting AMPK vs. ER stress pathway","pmids":["33337559"],"is_preprint":false},{"year":2021,"finding":"GDF15 acts via the GFRAL-RET receptor complex in area postrema/NTS excitatory neurons; single-nuclei RNA sequencing identified ~600 cell-type-specific transcriptomic changes in AP/NTS neurons and glia after systemic GDF15 treatment, mapping downstream signaling pathways specifically in Gfral/Ret-positive excitatory neurons.","method":"Single-nuclei RNA sequencing (snRNAseq) of rat AP/NTS micropunches after GDF15 injection, Seurat-based cell-type clustering, differential gene expression","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific transcriptomic profiling at single-nucleus resolution identifying downstream signaling, single lab","pmids":["34942400"],"is_preprint":false},{"year":2021,"finding":"Notch4 signaling on lung Treg cells upregulates GDF15 expression (via Wnt pathway), and this Treg-derived GDF15 activates group 2 innate lymphoid cells (ILC2s) to create a feed-forward loop promoting airway inflammation in asthma.","method":"Notch4-conditional mouse models, Wnt pathway inhibitor experiments, ILC2 activation assays, human asthma patient Treg analysis","journal":"Nature immunology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mouse models with defined inflammatory phenotype and ILC2 activation assay, but GDF15's direct receptor on ILC2s not characterized","pmids":["32929274"],"is_preprint":false},{"year":2022,"finding":"CNOT6L deadenylase controls the stability of hepatic Gdf15 mRNA; CNOT6L inhibition stabilizes Gdf15 mRNA, increasing serum GDF15 protein levels, which then suppresses appetite via hindbrain activation.","method":"CNOT6L genetic inhibition models, mRNA stability assays, serum GDF15 ELISA, food intake measurement, small-molecule CNOT6L inhibitor screening","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological manipulation of mRNA stability with defined protein output and physiological consequence, single lab","pmids":["35385705"],"is_preprint":false},{"year":2022,"finding":"A positive feedback loop exists between AMPK and GDF15 in the context of metformin action: metformin activates AMPK, which increases GDF15; GDF15 in turn sustains full AMPK activation in liver and skeletal muscle independently of the CNS/GFRAL. Gdf15-knockout mice show blunted AMPK activation in response to metformin, and Gdf15 knockdown in cultured hepatocytes and myotubes reduces metformin-induced AMPK activation.","method":"Gdf15-knockout mice, Gdf15 siRNA knockdown in hepatocytes/myotubes, metformin treatment, AMPK phosphorylation western blotting, glucose tolerance testing","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO and siRNA knockdown with defined signaling phenotype establishing AMPK-GDF15 feedback, single lab","pmids":["36435271"],"is_preprint":false},{"year":2022,"finding":"GDF15 knockdown decreases SLC7A11 (system Xc- transporter) expression, promoting erastin-induced ferroptosis in gastric cancer MGC803 cells. GDF15 knockdown reduces intracellular GSH and increases lipid ROS levels, and blocks the erastin-induced upregulation of SLC7A11, indicating GDF15 supports ferroptosis resistance via SLC7A11.","method":"GDF15 siRNA knockdown, CCK-8 cell viability assay, qRT-PCR and western blotting for SLC7A11, glutamate/GSH measurement, lipid ROS detection","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single knockdown approach without rescue or upstream mechanistic detail connecting GDF15 to SLC7A11 regulation","pmids":["32209255"],"is_preprint":false},{"year":2022,"finding":"GDF15 overexpression in transgenic mice inhibits HFD/STZ-induced non-alcoholic steatohepatitis by suppressing oxidative stress-mediated mitochondrial damage and double-strand DNA release into the cytosol, thereby blocking AIM2 inflammasome activation and reducing IL-18 and IL-1β secretion. This effect is independent of reduced food intake.","method":"NAG-1/GDF15 transgenic mice on HFD, free fatty acid-treated hepatocyte steatosis models, GDF15 siRNA knockdown, oxidative stress markers, dsDNA cytosolic release assay, AIM2 inflammasome activation assay (IL-18/IL-1β ELISA)","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic and knockdown models with defined inflammasome mechanistic pathway, corroborated in both in vivo and in vitro systems","pmids":["35504134"],"is_preprint":false},{"year":2022,"finding":"GDF15 NAG-1 inhibits HFD/STZ-induced diabetic nephropathy by inhibiting the AGE/RAGE axis and associated downstream TLR4/MyD88/NF-κB inflammatory signaling, as well as reducing adhesion molecules, in both transgenic mice and high-glucose-treated HK-2 renal tubular cells.","method":"NAG-1/GDF15 transgenic mice with HFD/STZ DN model, transcriptome analysis, recombinant GDF15 protein treatment of HK-2 cells, western blotting for AGE/RAGE, TLR4/MyD88/NF-κB pathway components","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic model with transcriptome plus in vitro recombinant protein confirmation identifying AGE/RAGE-NF-κB pathway, single lab","pmids":["36367498"],"is_preprint":false},{"year":2022,"finding":"GDF15 promotes skin pigmentation by stimulating melanogenesis through MITF/tyrosinase upregulation via β-catenin signaling in melanocytes. This effect is mediated by GDF15 secreted from UV-irradiated senescent fibroblasts.","method":"GDF15 lentiviral overexpression and shRNA knockdown in fibroblasts, co-culture of melanocytes with GDF15-expressing fibroblasts, β-catenin signaling analysis, ex vivo skin culture, reconstituted human skin model","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-culture system with lentiviral gain- and loss-of-function plus β-catenin pathway placement, ex vivo validation; single lab","pmids":["32416083"],"is_preprint":false},{"year":2022,"finding":"GDF15 expression in IPF lung-derived extracellular matrix is markedly elevated, and recombinant GDF15 stimulates α-smooth muscle actin (αSMA) expression in normal human lung fibroblasts through the ALK5 (TGF-β type I receptor) pathway. GDF15 neutralization in a bleomycin lung fibrosis mouse model significantly reduces fibrosis.","method":"3D spheroid fibroblast assay with IPF ECM, proteomics of IPF ECM, recombinant GDF15 stimulation with ALK5 inhibitor, αSMA expression, bleomycin lung fibrosis mouse model with GDF15 neutralizing antibody, collagen gel migration assay","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro ALK5 pathway dissection plus in vivo neutralization in fibrosis model, multiple assays; single lab","pmids":["35993367"],"is_preprint":false},{"year":2023,"finding":"In addition to suppressing appetite via GFRAL, GDF15 counteracts adaptive thermogenesis (compensatory energy expenditure reduction) during caloric restriction. This effect requires a GFRAL-β-adrenergic receptor-dependent signaling axis that increases fatty acid oxidation and calcium futile cycling in skeletal muscle, resulting in maintained energy expenditure during weight loss.","method":"Recombinant GDF15 treatment in calorie-restricted mice, GFRAL-knockout mice, β-adrenergic blocker pharmacology, skeletal muscle fatty acid oxidation assays, calcium cycling measurements, NAFLD assessment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic GFRAL-KO and pharmacological β-adrenergic blockade converge on the same mechanism; multiple metabolic readouts in defined mouse models","pmids":["37380764"],"is_preprint":false},{"year":2023,"finding":"GDF15 and leptin synergize in the hindbrain to enhance weight and adiposity loss; LepR-expressing neurons in the NTS are extensively connected with GFRAL-expressing neurons, and LepR knockdown in the NTS reduces GDF15-mediated activation of area postrema neurons, establishing that leptin receptor signaling in the hindbrain potentiates GDF15's metabolic actions.","method":"Combined GDF15 and leptin infusion in HFD mice, competitive leptin antagonist in normal mice, ob/ob mice (leptin-deficient), AAV-mediated LepR knockdown in NTS, hindbrain neuronal activation mapping","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — genetic (ob/ob, AAV-KD) and pharmacological (leptin antagonist) approaches plus neuronal circuit mapping; single lab","pmids":["37433299"],"is_preprint":false},{"year":2023,"finding":"GDF15 ameliorates liver fibrosis by reprogramming macrophage metabolic pathways toward oxidative phosphorylation, inducing an anti-inflammatory functional fate. Adoptive transfer of GDF15-preprogrammed macrophages to CCl4 fibrosis mouse models attenuates inflammation and liver fibrosis progression.","method":"Gdf15-knockout mice in CCl4 and DDC diet fibrosis models, AAV8-mediated GDF15 overexpression in hepatocytes, recombinant GDF15 treatment, CyTOF/flow cytometry for immune profiling, metabolic flux analysis of macrophages, adoptive transfer of GDF15-preprogrammed macrophages","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO, gene delivery, and adoptive transfer provide orthogonal evidence for macrophage reprogramming mechanism; single lab","pmids":["37499753"],"is_preprint":false},{"year":2024,"finding":"GDF15 activates hepatic AMPK and inhibits gluconeogenesis and fibrosis by attenuating the TGF-β1/SMAD3 pathway independently of its central receptor GFRAL. Gdf15-knockout mice show reduced hepatic AMPK phosphorylation, elevated pSMAD3, increased TGF-β1, and enhanced gluconeogenesis/fibrosis. Recombinant GDF15 in primary hepatocytes reduces pSMAD3 and gluconeogenic markers, and pharmacological SMAD3 inhibition in Gdf15-KO mice rescues AMPK activity and metabolic phenotype.","method":"Gdf15-knockout mice, recombinant GDF15 in primary hepatocytes and Huh-7 cells, SMAD3 pharmacological inhibition, AMPK phosphorylation western blotting, gluconeogenic gene expression, liver fibrosis histology","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 — KO model plus recombinant protein plus pharmacological rescue identifying TGF-β1/SMAD3-AMPK axis; GFRAL-independence suggested but receptor for this peripheral effect not identified","pmids":["38176644"],"is_preprint":false},{"year":2024,"finding":"Cardiac stress upregulates GDF15 expression in cardiomyocytes via ISR/eIF2α phosphatase (PPP1R15A) pathway, and elevated circulating GDF15 drives weight loss and worsens cardiac function (cardiac cachexia). GDF15 blockade prevents cachexia and slows heart failure progression in a dilated cardiomyopathy mouse model.","method":"PPP1R15A-knockout mouse model with irradiation-induced dilated cardiomyopathy, cardiac GDF15 expression analysis, GDF15 blocking antibody treatment, lean mass and cardiac function measurements","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic model with defined cardiac phenotype plus antibody blockade demonstrating GDF15-dependent cardiac cachexia; single lab","pmids":["39312445"],"is_preprint":false}],"current_model":"GDF15 is a stress-responsive, secreted TGF-β superfamily dimeric cytokine that signals primarily through a brainstem-restricted GFRAL-RET heterodimeric receptor complex expressed exclusively in area postrema and nucleus tractus solitarius neurons, activating downstream PI3K-Akt and sympathetic nervous system pathways to suppress appetite, induce conditioned taste aversion, and counteract adaptive thermogenesis via a GFRAL-β-adrenergic-skeletal muscle axis; it is transcriptionally induced by p53, ATF4/CHOP (integrated stress response), and AMPK, undergoes Golgi-dependent proteolytic maturation facilitated by ARRB1, and in addition to its central effects exerts peripheral actions including hepcidin suppression (contributing to iron overload in thalassemia), cardioprotection via PI3K-Akt1, macrophage metabolic reprogramming, fibroblast ALK5-dependent pro-fibrotic signaling, and SMAD3 pathway attenuation to regulate hepatic gluconeogenesis and fibrosis."},"narrative":{"teleology":[{"year":1997,"claim":"Identifying GDF15 as a new TGF-β superfamily member secreted as a disulfide-linked dimer from macrophages established its biochemical identity and initial autocrine anti-inflammatory function.","evidence":"Subtraction cloning from activated macrophages, recombinant protein purification from CHO cells, and functional TNF-α inhibition assay","pmids":["9326641"],"confidence":"High","gaps":["Receptor identity unknown","In vivo relevance of macrophage regulation not tested","Signaling pathway downstream of GDF15 not identified"]},{"year":2000,"claim":"Demonstrating that p53 directly binds and transactivates the GDF15 promoter linked GDF15 to the tumor suppressor network and explained its stress-inducible expression pattern.","evidence":"EMSA with recombinant p53, promoter-luciferase reporters, and adenoviral overexpression causing G1 arrest and apoptosis in breast cancer cells","pmids":["10777512"],"confidence":"High","gaps":["Other stress-responsive transcription factors not yet mapped","Whether p53-GDF15 axis operates in non-cancer contexts unclear"]},{"year":2006,"claim":"The finding that Gdf15-knockout mice develop larger infarcts and that recombinant GDF15 rescues cardiomyocyte survival via PI3K-Akt1 established GDF15 as a cardioprotective cytokine with a defined survival signaling pathway.","evidence":"Gdf15-KO mice with coronary ligation, recombinant GDF15 rescue, PI3K inhibitor and dominant-negative Akt1 blockade","pmids":["16397141"],"confidence":"High","gaps":["Receptor mediating cardiac PI3K-Akt1 activation unknown","Whether cardioprotection is paracrine or autocrine not resolved"]},{"year":2007,"claim":"Discovery that tumor-derived GDF15 causes cancer-associated anorexia reversible by neutralizing antibody, and that erythroid GDF15 suppresses hepatic hepcidin in β-thalassemia, revealed two major systemic endocrine functions.","evidence":"Prostate cancer xenograft models with anti-MIC-1 antibody reversal; β-thalassemia patient serum immunodepletion restoring hepcidin in primary hepatocytes","pmids":["17982462","17721544"],"confidence":"High","gaps":["Central receptor not identified","Receptor mediating hepcidin suppression unknown","Relative contribution of GDF15 vs. other erythroid factors to iron overload not quantified"]},{"year":2017,"claim":"Four independent groups simultaneously identified GFRAL as the high-affinity receptor for GDF15, restricted to area postrema and NTS neurons and requiring RET as a co-receptor, resolving the two-decade-old receptor question and defining the neural circuit for appetite suppression.","evidence":"Receptor binding assays, Gfral-KO mice refractory to GDF15-induced anorexia, GFRAL monoclonal antibody blockade, ISH/IHC localization, RET co-receptor signaling studies, c-Fos neuronal activation mapping","pmids":["28846097","28846098","28953886","28846099"],"confidence":"High","gaps":["Peripheral receptor(s) mediating GFRAL-independent effects remain unidentified","Downstream intracellular signaling in GFRAL+ neurons incompletely mapped","Whether GFRAL has additional ligands unknown"]},{"year":2019,"claim":"Integrated stress response transcription factors ATF4/CHOP and dietary/pharmacological stressors were shown to drive GDF15 expression, and GDF15 was established as the required mediator of metformin's anorectic and weight-lowering effects in mice and humans, while conditioned taste aversion experiments revealed an aversive rather than classical satiety mechanism.","evidence":"GDF15-null mice unresponsive to metformin weight loss, two independent RCTs showing metformin increases circulating GDF15, ISR pathway analysis, GFRAL antagonist antibody, conditioned taste aversion behavioral assay","pmids":["32694673","31875646","30639358"],"confidence":"High","gaps":["Whether metformin-GDF15 axis is relevant in lean individuals unknown","Precise neural mechanism translating GFRAL activation to malaise not defined","Tissue source hierarchy for metformin-induced GDF15 not fully resolved"]},{"year":2019,"claim":"ARRB1 was identified as a direct interactor of pro-GDF15 required for its Golgi transport and proteolytic maturation, revealing a previously unknown step in GDF15 secretory processing.","evidence":"Co-IP of ARRB1 with pro-GDF15, Arrb1-KO mice with impaired GDF15 maturation and steatohepatitis rescued by recombinant GDF15, subcellular fractionation","pmids":["31857195"],"confidence":"Medium","gaps":["Protease responsible for pro-GDF15 cleavage not identified","Whether ARRB1 role is specific to GDF15 or shared with other TGF-β family members unknown","Single-lab finding awaiting independent replication"]},{"year":2020,"claim":"Mapping the peripheral effector arm showed that GDF15-GFRAL signaling activates sympathetic outflow requiring ATGL for adipose lipolysis, and that GDF15 induces visceral malaise distinct from GLP-1 receptor agonist mechanisms.","evidence":"GFRAL antagonist antibody, chemical sympathectomy, ATGL-KO mice in cachexia models; rat behavioral paradigms with fiber photometry comparing GDF15 vs. semaglutide","pmids":["32661391","35129264"],"confidence":"High","gaps":["Whether sympathetic axis mediates GDF15's effects on muscle wasting not resolved","Neural pathway from AP/NTS to sympathetic outflow not fully traced"]},{"year":2021,"claim":"AMPKβ1 was identified as a stress-responsive transcriptional inducer of hepatic GDF15 independent of ER stress/CHOP, expanding the regulatory inputs beyond the canonical ISR.","evidence":"AMPKβ1-KO and CHOP-KO mice treated with three pharmacological AMPK activators, hepatic Gdf15 expression and serum measurements","pmids":["33337559"],"confidence":"High","gaps":["Transcription factor downstream of AMPK that directly drives GDF15 promoter not identified","Whether AMPKβ1 and ATF4/CHOP pathways converge or are fully independent in vivo unclear"]},{"year":2022,"claim":"Post-transcriptional control of GDF15 was revealed through CNOT6L deadenylase regulation of Gdf15 mRNA stability, and peripheral anti-inflammatory mechanisms were expanded to include AIM2 inflammasome suppression and AGE/RAGE-NF-κB inhibition in liver and kidney disease models.","evidence":"CNOT6L genetic inhibition stabilizing Gdf15 mRNA; GDF15-transgenic mice showing reduced AIM2 activation in NASH and reduced TLR4/NF-κB in diabetic nephropathy","pmids":["35385705","35504134","36367498"],"confidence":"Medium","gaps":["Whether CNOT6L regulation is tissue-specific not established","Receptor mediating GDF15's peripheral anti-inflammatory effects unknown","No structural basis for GDF15-mRNA deadenylase interaction"]},{"year":2022,"claim":"GDF15 was shown to signal through ALK5 (TGF-β type I receptor) in lung fibroblasts to drive α-SMA expression, and GDF15 neutralization reduced bleomycin-induced lung fibrosis, revealing a pro-fibrotic peripheral signaling axis.","evidence":"Recombinant GDF15 with ALK5 inhibitor in fibroblasts, IPF ECM proteomics, bleomycin mouse model with GDF15 neutralizing antibody","pmids":["35993367"],"confidence":"Medium","gaps":["Whether ALK5 is a direct GDF15 receptor or requires a co-receptor not determined","Relationship between ALK5 signaling and GFRAL-independent effects in other tissues unknown"]},{"year":2023,"claim":"GDF15 was found to counteract adaptive thermogenesis during caloric restriction through a GFRAL–β-adrenergic–skeletal muscle axis driving fatty acid oxidation and calcium futile cycling, providing a mechanism for sustained energy expenditure during weight loss beyond appetite suppression.","evidence":"GFRAL-KO mice under caloric restriction, β-blocker pharmacology, skeletal muscle fatty acid oxidation and calcium cycling assays","pmids":["37380764"],"confidence":"High","gaps":["Whether this anti-thermogenic-adaptation pathway operates in humans not tested","Molecular identity of muscle calcium cycling targets downstream of β-adrenergic signaling not specified"]},{"year":2023,"claim":"GDF15 was shown to reprogram macrophages toward oxidative phosphorylation and an anti-inflammatory phenotype, and adoptive transfer of GDF15-conditioned macrophages attenuated liver fibrosis, while leptin receptor signaling in NTS was found to potentiate GDF15's central metabolic effects.","evidence":"Gdf15-KO mice in CCl4/DDC fibrosis models, adoptive macrophage transfer, CyTOF immune profiling, metabolic flux analysis; combined GDF15-leptin infusion with AAV-LepR knockdown in NTS","pmids":["37499753","37433299"],"confidence":"Medium","gaps":["Receptor mediating GDF15's macrophage reprogramming not identified","Whether leptin-GDF15 synergy occurs in humans unknown","Degree to which macrophage reprogramming vs. direct hepatocyte effects drive anti-fibrotic action not resolved"]},{"year":2024,"claim":"Hepatic GFRAL-independent GDF15 signaling was mapped to SMAD3 pathway attenuation that restores AMPK activity and suppresses gluconeogenesis and fibrosis, while cardiac ISR-driven GDF15 was identified as a mediator of cardiac cachexia blockable by GDF15 antibody.","evidence":"Gdf15-KO mice with elevated pSMAD3 and gluconeogenesis rescued by SMAD3 inhibitor; PPP1R15A-KO dilated cardiomyopathy model with GDF15 blocking antibody preventing cachexia","pmids":["38176644","39312445"],"confidence":"Medium","gaps":["Peripheral hepatic receptor for GDF15 that mediates SMAD3 attenuation not identified","Whether cardiac GDF15 blockade is therapeutically viable without compromising stress-protective functions unknown","Structural basis for GDF15-SMAD3 pathway interaction not established"]},{"year":null,"claim":"The identity of peripheral receptor(s) mediating GDF15's GFRAL-independent effects on macrophages, hepatocytes, and fibroblasts remains the central unresolved question; proposed interactors (ErbB2, CD48, ALK5) each derive from single laboratories and await independent validation and structural characterization.","evidence":"","pmids":[],"confidence":"Low","gaps":["No consensus peripheral receptor identified","No crystal structure of full-length GDF15-GFRAL-RET ternary complex","Therapeutic window between beneficial metabolic effects and detrimental cachexia/aversion not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,4,8,9,16,30]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,5,32,33]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,4,5,7,8,14,16]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,8,9,16,30,33]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,17,22,32]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[6,7,12,14,20,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,2,3]}],"complexes":[],"partners":["GFRAL","RET","ARRB1","TP53","ATF4","DDIT3","PRKAB1"],"other_free_text":[]},"mechanistic_narrative":"GDF15 is a stress-responsive, secreted TGF-β superfamily cytokine that functions as a central regulator of energy balance, appetite, and tissue-protective responses across multiple organ systems. It is synthesized as a propeptide, undergoes proteolytic maturation facilitated by ARRB1-mediated Golgi transport, and is secreted as a disulfide-linked dimer whose transcription is driven by p53, ATF4/CHOP (integrated stress response), and AMPKβ1 [PMID:9326641, PMID:10777512, PMID:32694673, PMID:33337559, PMID:31857195]. Circulating GDF15 signals through the brainstem-restricted GFRAL–RET receptor tyrosine kinase complex in area postrema/nucleus tractus solitarius neurons to suppress food intake via conditioned aversion, activate sympathetic outflow that drives peripheral lipolysis through ATGL, and counteract adaptive thermogenesis via β-adrenergic–skeletal muscle fatty acid oxidation and calcium futile cycling [PMID:28846097, PMID:28953886, PMID:32661391, PMID:37380764, PMID:30639358]. Beyond its central metabolic actions, GDF15 exerts GFRAL-independent peripheral effects including cardioprotection via PI3K-Akt1 signaling, suppression of hepatic gluconeogenesis and fibrosis through SMAD3 pathway attenuation, macrophage metabolic reprogramming toward oxidative phosphorylation, hepcidin suppression contributing to iron overload in β-thalassemia, and pro-fibrotic ALK5-dependent signaling in lung fibroblasts [PMID:16397141, PMID:38176644, PMID:37499753, PMID:17721544, PMID:35993367]."},"prefetch_data":{"uniprot":{"accession":"Q99988","full_name":"Growth/differentiation factor 15","aliases":["Macrophage inhibitory cytokine 1","MIC-1","NSAID-activated gene 1 protein","NAG-1","NSAID-regulated gene 1 protein","NRG-1","Placental TGF-beta","Placental bone morphogenetic protein","Prostate differentiation factor"],"length_aa":308,"mass_kda":34.1,"function":"Hormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite (PubMed:23468844, PubMed:24971956, PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:29046435, PubMed:30639358, PubMed:31875646, PubMed:33589633, PubMed:38092039). The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future (PubMed:30639358, PubMed:33589633, PubMed:38092039). Acts by binding to its receptor, GFRAL, activating GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:31535977). It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which constitutes part of the 'emergency circuit' that shapes responses to stressful conditions (PubMed:28953886). The GDF15-GFRAL signal induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues (PubMed:31402172). Required for avoidance behavior in response to food allergens: induced downstream of mast cell activation to promote aversion and minimize harmful effects of exposure to noxious substances (By similarity). In addition to suppress appetite, also promotes weight loss by enhancing energy expenditure in muscle: acts by increasing calcium futile cycling in muscle (By similarity). Contributes to the effect of metformin, an anti-diabetic drug, on appetite reduction and weight loss: produced in the kidney in response to metformin treatment, thereby activating the GDF15-GFRAL response, leading to reduced appetite and weight (PubMed:31875646, PubMed:37060902). The contribution of GDF15 to weight loss following metformin treatment is however limited and subject to discussion (PubMed:36001956). Produced in response to anticancer drugs, such as camptothecin or cisplatin, promoting nausea, vomiting and contributing to malnutrition (By similarity). Overproduced in many cancers, promoting anorexia in cancer (cachexia) (PubMed:32661391). Responsible for the risk of nausea and vomiting during pregnancy: high levels of GDF15 during pregnancy, mostly originating from the fetus, are associated with increased nausea and vomiting (PubMed:38092039). Maternal sensitivity to nausea is probably determined by pre-pregnancy exposure to GDF15, women with naturally high level of GDF15 being less susceptible to nausea than women with low levels of GDF15 before pregnancy (PubMed:38092039). Promotes metabolic adaptation in response to systemic inflammation caused by bacterial and viral infections in order to promote tissue tolerance and prevent tissue damage (PubMed:31402172). Required for tissue tolerance in response to myocardial infarction by acting as an inhibitor of leukocyte integring activation, thereby protecting against cardiac rupture (By similarity). Inhibits growth hormone signaling on hepatocytes (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q99988/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GDF15","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GDF15","total_profiled":1310},"omim":[{"mim_id":"621503","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 39; LRRC39","url":"https://www.omim.org/entry/621503"},{"mim_id":"621298","title":"GLYCINE-RICH EXTRACELLULAR PROTEIN 1; GREP1","url":"https://www.omim.org/entry/621298"},{"mim_id":"620730","title":"HYPEREMESIS GRAVIDARUM, SUSCEPTIBILITY TO; HG","url":"https://www.omim.org/entry/620730"},{"mim_id":"619538","title":"CEREBRAL CAVERNOUS MALFORMATIONS 4; CCM4","url":"https://www.omim.org/entry/619538"},{"mim_id":"617837","title":"GDNF FAMILY RECEPTOR ALPHA-LIKE PROTEIN; GFRAL","url":"https://www.omim.org/entry/617837"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Golgi apparatus","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"kidney","ntpm":328.4}],"url":"https://www.proteinatlas.org/search/GDF15"},"hgnc":{"alias_symbol":["PLAB","MIC-1","PDF","MIC1","NAG-1","PTGFB"],"prev_symbol":[]},"alphafold":{"accession":"Q99988","domains":[{"cath_id":"2.10.90.10","chopping":"213-308","consensus_level":"high","plddt":94.7713,"start":213,"end":308},{"cath_id":"2.40.30","chopping":"86-168_176-187","consensus_level":"high","plddt":75.5677,"start":86,"end":187}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99988","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99988-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99988-F1-predicted_aligned_error_v6.png","plddt_mean":75.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GDF15","jax_strain_url":"https://www.jax.org/strain/search?query=GDF15"},"sequence":{"accession":"Q99988","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99988.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99988/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99988"}},"corpus_meta":[{"pmid":"28846097","id":"PMC_28846097","title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846097","citation_count":615,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28846098","id":"PMC_28846098","title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846098","citation_count":541,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28953886","id":"PMC_28953886","title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28953886","citation_count":500,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31875646","id":"PMC_31875646","title":"GDF15 mediates the effects of metformin on body weight and energy balance.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31875646","citation_count":437,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34381196","id":"PMC_34381196","title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.","date":"2021","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34381196","citation_count":393,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30639358","id":"PMC_30639358","title":"GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans.","date":"2019","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30639358","citation_count":393,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30184485","id":"PMC_30184485","title":"The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.","date":"2018","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30184485","citation_count":331,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16242402","id":"PMC_16242402","title":"PDF receptor signaling in Drosophila contributes to both circadian and geotactic behaviors.","date":"2005","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/16242402","citation_count":265,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32661391","id":"PMC_32661391","title":"Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.","date":"2020","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32661391","citation_count":253,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9375789","id":"PMC_9375789","title":"PLAB, a novel placental bone morphogenetic protein.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9375789","citation_count":217,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24531647","id":"PMC_24531647","title":"NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism.","date":"2014","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/24531647","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32310257","id":"PMC_32310257","title":"GDF15: A Hormone Conveying Somatic Distress to the Brain.","date":"2020","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32310257","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29046435","id":"PMC_29046435","title":"Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29046435","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37380764","id":"PMC_37380764","title":"GDF15 promotes weight loss by enhancing energy expenditure in muscle.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37380764","citation_count":183,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33228454","id":"PMC_33228454","title":"The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?","date":"2020","source":"Annual review of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33228454","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29636108","id":"PMC_29636108","title":"GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29636108","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30790643","id":"PMC_30790643","title":"Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases.","date":"2019","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30790643","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30542297","id":"PMC_30542297","title":"GDF15 and Growth Control.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30542297","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26497212","id":"PMC_26497212","title":"GDF15 promotes EMT and metastasis in colorectal cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26497212","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34489334","id":"PMC_34489334","title":"GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34489334","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35051643","id":"PMC_35051643","title":"GDF15, an emerging key player in human aging.","date":"2022","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35051643","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33172749","id":"PMC_33172749","title":"Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets.","date":"2020","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/33172749","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34836750","id":"PMC_34836750","title":"Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.","date":"2021","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34836750","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34445593","id":"PMC_34445593","title":"GDF15 and Cardiac Cells: Current Concepts and New Insights.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445593","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33589633","id":"PMC_33589633","title":"Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33589633","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32936319","id":"PMC_32936319","title":"GDF15, an update of the physiological and pathological roles it plays: a review.","date":"2020","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32936319","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17129398","id":"PMC_17129398","title":"NSAID activated gene (NAG-1), a modulator of tumorigenesis.","date":"2006","source":"Journal of biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17129398","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32929274","id":"PMC_32929274","title":"A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.","date":"2020","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32929274","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35504134","id":"PMC_35504134","title":"Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35504134","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29866502","id":"PMC_29866502","title":"Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.","date":"2018","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/29866502","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34831213","id":"PMC_34831213","title":"The Role of GDF15 as a Myomitokine.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34831213","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31411815","id":"PMC_31411815","title":"Brown Adipocytes Secrete GDF15 in Response to Thermogenic Activation.","date":"2019","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31411815","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29161287","id":"PMC_29161287","title":"TGF-β contamination of purified recombinant GDF15.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29161287","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35058441","id":"PMC_35058441","title":"GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation.","date":"2022","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/35058441","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11205146","id":"PMC_11205146","title":"GDF-15/MIC-1 a novel member of the TGF-beta superfamily.","date":"2000","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/11205146","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32209255","id":"PMC_32209255","title":"GDF15 knockdown promotes erastin-induced ferroptosis by decreasing SLC7A11 expression.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32209255","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11447133","id":"PMC_11447133","title":"Toxoplasma gondii micronemal protein MIC1 is a lactose-binding lectin.","date":"2001","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/11447133","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31857195","id":"PMC_31857195","title":"ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.","date":"2019","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31857195","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16616574","id":"PMC_16616574","title":"Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii.","date":"2006","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/16616574","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27585848","id":"PMC_27585848","title":"The Neuropeptides FLP-2 and PDF-1 Act in Concert To Arouse Caenorhabditis elegans Locomotion.","date":"2016","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27585848","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19325135","id":"PMC_19325135","title":"PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19325135","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36367498","id":"PMC_36367498","title":"NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36367498","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37499753","id":"PMC_37499753","title":"GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties.","date":"2023","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37499753","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35993367","id":"PMC_35993367","title":"Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35993367","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31000883","id":"PMC_31000883","title":"Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality.","date":"2019","source":"Geburtshilfe und Frauenheilkunde","url":"https://pubmed.ncbi.nlm.nih.gov/31000883","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27852781","id":"PMC_27852781","title":"Drosophila DH31 Neuropeptide and PDF Receptor Regulate Night-Onset Temperature Preference.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27852781","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32504264","id":"PMC_32504264","title":"Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients.","date":"2020","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/32504264","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35129264","id":"PMC_35129264","title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms.","date":"2022","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35129264","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34849709","id":"PMC_34849709","title":"GDF15 in Appetite and Exercise: Essential Player or Coincidental Bystander?","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34849709","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26741507","id":"PMC_26741507","title":"Control of glioma cell migration and invasiveness by GDF-15.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26741507","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35385705","id":"PMC_35385705","title":"Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35385705","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36444166","id":"PMC_36444166","title":"Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.","date":"2022","source":"Journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/36444166","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33337559","id":"PMC_33337559","title":"AMPK mediates energetic stress-induced liver GDF15.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33337559","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29653105","id":"PMC_29653105","title":"CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29653105","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23583112","id":"PMC_23583112","title":"GW182 controls Drosophila circadian behavior and PDF-receptor signaling.","date":"2013","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/23583112","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38810400","id":"PMC_38810400","title":"Overview of growth differentiation factor 15 (GDF15) in metabolic diseases.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38810400","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34294853","id":"PMC_34294853","title":"The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34294853","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25548048","id":"PMC_25548048","title":"Iron corrosion induced by nonhydrogenotrophic nitrate-reducing Prolixibacter sp. strain MIC1-1.","date":"2014","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/25548048","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29967567","id":"PMC_29967567","title":"CRP Stimulates GDF15 Expression in Endothelial Cells through p53.","date":"2018","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29967567","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32416083","id":"PMC_32416083","title":"Senescent Fibroblast-Derived GDF15 Induces Skin Pigmentation.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32416083","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32322241","id":"PMC_32322241","title":"Genomic Analysis of Mic1 Reveals a Novel Freshwater Long-Tailed Cyanophage.","date":"2020","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32322241","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38176644","id":"PMC_38176644","title":"GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/38176644","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36001956","id":"PMC_36001956","title":"The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36001956","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22579613","id":"PMC_22579613","title":"PDF receptor signaling in Caenorhabditis elegans modulates locomotion and egg-laying.","date":"2012","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22579613","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30633545","id":"PMC_30633545","title":"GDF-15 in Pulmonary and Critical Care Medicine.","date":"2019","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30633545","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37093513","id":"PMC_37093513","title":"GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing.","date":"2023","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37093513","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29724997","id":"PMC_29724997","title":"Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29724997","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36142823","id":"PMC_36142823","title":"GDF15 Contributes to Radioresistance by Mediating the EMT and Stemness of Breast Cancer Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142823","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37433299","id":"PMC_37433299","title":"GDF15 enhances body weight and adiposity reduction in obese mice by leveraging the leptin pathway.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37433299","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33188737","id":"PMC_33188737","title":"Mitochondrial stress and GDF15 in the pathophysiology of sepsis.","date":"2020","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33188737","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36435271","id":"PMC_36435271","title":"A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36435271","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32304740","id":"PMC_32304740","title":"Functional roles of GDF15 in modulating microenvironment to promote carcinogenesis.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32304740","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22116686","id":"PMC_22116686","title":"A new MIC1-MAG1 recombinant chimeric antigen can be used instead of the Toxoplasma gondii lysate antigen in serodiagnosis of human toxoplasmosis.","date":"2011","source":"Clinical and vaccine immunology : CVI","url":"https://pubmed.ncbi.nlm.nih.gov/22116686","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34566964","id":"PMC_34566964","title":"The Clinical Value of GDF15 and Its Prospective Mechanism in Sepsis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34566964","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35202387","id":"PMC_35202387","title":"Camptothecin effectively treats obesity in mice through GDF15 induction.","date":"2022","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/35202387","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31172564","id":"PMC_31172564","title":"GDF15 induced apoptosis and cytotoxicity in A549 cells depends on TGFBR2 expression.","date":"2019","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/31172564","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30947652","id":"PMC_30947652","title":"GDF-15: A Multifunctional Modulator and Potential Therapeutic Target in Cancer.","date":"2019","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/30947652","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34208730","id":"PMC_34208730","title":"Quercetin Induces Anticancer Activity by Upregulating Pro-NAG-1/GDF15 in Differentiated Thyroid Cancer Cells.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34208730","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39472228","id":"PMC_39472228","title":"GDF15 is still a mystery hormone.","date":"2024","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/39472228","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39312445","id":"PMC_39312445","title":"GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.","date":"2024","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39312445","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19640837","id":"PMC_19640837","title":"Phospholipase PlaB of Legionella pneumophila represents a novel lipase family: protein residues essential for lipolytic activity, substrate specificity, and hemolysis.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19640837","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31378451","id":"PMC_31378451","title":"Capsid Structure of a Freshwater Cyanophage Siphoviridae Mic1.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31378451","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30635935","id":"PMC_30635935","title":"GDF-15 promotes mitochondrial function and proliferation in neuronal HT22 cells.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30635935","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34117368","id":"PMC_34117368","title":"Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression.","date":"2021","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/34117368","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21205743","id":"PMC_21205743","title":"The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.","date":"2011","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/21205743","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39000420","id":"PMC_39000420","title":"Macrophages as a Source and Target of GDF-15.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39000420","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25052873","id":"PMC_25052873","title":"Hepcidin and GDF15 in anemia of multiple myeloma.","date":"2014","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25052873","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30696873","id":"PMC_30696873","title":"Neuropeptides PDF and DH31 hierarchically regulate free-running rhythmicity in Drosophila circadian locomotor activity.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30696873","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35138971","id":"PMC_35138971","title":"GDF15: a potential therapeutic target for type 1 diabetes.","date":"2022","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/35138971","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36465107","id":"PMC_36465107","title":"Hepatocyte-derived GDF15 suppresses feeding and improves insulin sensitivity in obese mice.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36465107","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36720918","id":"PMC_36720918","title":"BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36720918","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32614434","id":"PMC_32614434","title":"The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32614434","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34942400","id":"PMC_34942400","title":"Single nuclei RNA sequencing of the rat AP and NTS following GDF15 treatment.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34942400","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36205439","id":"PMC_36205439","title":"Growth and differentiation factor 15 (GDF15) levels predict adverse respiratory outcomes in premature neonates.","date":"2022","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/36205439","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21809352","id":"PMC_21809352","title":"The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo.","date":"2011","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/21809352","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30382947","id":"PMC_30382947","title":"Targeting the divergent TGFβ superfamily cytokine MIC-1/GDF15 for therapy of anorexia/cachexia syndromes.","date":"2018","source":"Current opinion in supportive and palliative care","url":"https://pubmed.ncbi.nlm.nih.gov/30382947","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31474335","id":"PMC_31474335","title":"Competitive inhibition by NAG-1/GDF-15 NLS peptide enhances its anti-cancer activity.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31474335","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39643709","id":"PMC_39643709","title":"GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process.","date":"2024","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/39643709","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25702523","id":"PMC_25702523","title":"New recombinant chimeric antigens, P35-MAG1, MIC1-ROP1, and MAG1-ROP1, for the serodiagnosis of human toxoplasmosis.","date":"2015","source":"Diagnostic microbiology and infectious disease","url":"https://pubmed.ncbi.nlm.nih.gov/25702523","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38892145","id":"PMC_38892145","title":"GDF15, an Emerging Player in Renal Physiology and Pathophysiology.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38892145","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32353859","id":"PMC_32353859","title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32353859","citation_count":3411,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9326641","id":"PMC_9326641","title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9326641","citation_count":1030,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060904","id":"PMC_19060904","title":"An empirical framework for binary interactome mapping.","date":"2008","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/19060904","citation_count":652,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17721544","id":"PMC_17721544","title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17721544","citation_count":646,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33060197","id":"PMC_33060197","title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33060197","citation_count":564,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16397141","id":"PMC_16397141","title":"The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16397141","citation_count":546,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28846099","id":"PMC_28846099","title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846099","citation_count":538,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17982462","id":"PMC_17982462","title":"Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17982462","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28062617","id":"PMC_28062617","title":"Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.","date":"2016","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28062617","citation_count":442,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12624183","id":"PMC_12624183","title":"Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12624183","citation_count":404,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26273671","id":"PMC_26273671","title":"GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.","date":"2015","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/26273671","citation_count":370,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11259636","id":"PMC_11259636","title":"Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11259636","citation_count":341,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27986797","id":"PMC_27986797","title":"Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis.","date":"2016","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27986797","citation_count":301,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9593718","id":"PMC_9593718","title":"Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9593718","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25294786","id":"PMC_25294786","title":"Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.","date":"2014","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/25294786","citation_count":259,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20855664","id":"PMC_20855664","title":"Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20855664","citation_count":254,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32694673","id":"PMC_32694673","title":"Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.","date":"2019","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694673","citation_count":243,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26463265","id":"PMC_26463265","title":"Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders.","date":"2015","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26463265","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20854422","id":"PMC_20854422","title":"Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality.","date":"2010","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/20854422","citation_count":240,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12855642","id":"PMC_12855642","title":"MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma.","date":"2003","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/12855642","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10777512","id":"PMC_10777512","title":"Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10777512","citation_count":236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15073115","id":"PMC_15073115","title":"Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15073115","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12090982","id":"PMC_12090982","title":"Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study.","date":"2002","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12090982","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9426002","id":"PMC_9426002","title":"Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9426002","citation_count":190,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45690,"output_tokens":5854,"usd":0.11244},"stage2":{"model":"claude-opus-4-6","input_tokens":9535,"output_tokens":2832,"usd":0.177712},"total_usd":0.708564,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60751,"output_tokens":9618,"usd":0.163262},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13770,"output_tokens":4050,"usd":0.25515}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"GDF15 binds with high affinity to GDNF family receptor α-like (GFRAL), expressed exclusively in neurons of the area postrema and nucleus of the solitary tract in the brainstem. Genetic deletion of GFRAL abrogates GDF15-induced decreases in food intake and body weight in mice. GDF15-induced cell signaling requires the interaction of GFRAL with the co-receptor RET.\",\n      \"method\": \"Receptor binding assays, Gfral knockout mice, genetic deletion studies, co-receptor interaction assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — independently replicated by four simultaneous papers (PMIDs 28846097, 28846098, 28953886) using binding assays, knockout mice, and functional readouts\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28953886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GFRAL is expressed in the area postrema and nucleus tractus solitarius of the brainstem. GDF15 activates GFRAL-expressing neurons, which then trigger activation of neurons in the parabrachial nucleus and central amygdala as part of an 'emergency circuit' regulating feeding responses to stress. Gfral knockout mice are hyperphagic under stressed conditions and resistant to chemotherapy-induced anorexia.\",\n      \"method\": \"Gfral knockout mice, neuronal activation studies (c-Fos), circuit tracing, in situ hybridization\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype plus circuit mapping, replicated across multiple labs\",\n      \"pmids\": [\"28953886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Metformin increases circulating GDF15 levels (predominantly expressed in distal intestine and kidney in mice), and the weight-lowering effects of metformin are dependent on GDF15 and its receptor GFRAL. Metformin-induced effects on energy intake and energy expenditure require GDF15 activity, whereas glucose-lowering effects are preserved in the absence of GDF15.\",\n      \"method\": \"Gdf15 knockout mice, GFRAL-antagonist antibody treatment, randomized controlled clinical trials (human), oral metformin dosing\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice plus GFRAL antagonist antibody plus human RCT data, multiple orthogonal methods\",\n      \"pmids\": [\"31875646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Antibody-mediated blockade of GFRAL (antibody 3P10) inhibits RET signaling by preventing GDF15-driven interaction of RET with GFRAL on the cell surface. GFRAL-RET pathway activation induces expression of lipid metabolism genes in adipose tissue, and GDF15-induced weight loss involves a peripheral sympathetic lipolytic axis in adipose tissue independent of anorexia. Peripheral chemical sympathectomy and loss of adipose triglyceride lipase protect mice from GDF15-induced weight loss.\",\n      \"method\": \"Antagonistic monoclonal antibody, chemical sympathectomy, adipose triglyceride lipase knockout mice, gene expression analysis of adipose tissue\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological tools with defined downstream molecular mechanisms\",\n      \"pmids\": [\"32661391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 counteracts compensatory reductions in energy expenditure (adaptive thermogenesis) during caloric restriction via a GFRAL-β-adrenergic-dependent signalling axis that increases fatty acid oxidation and calcium futile cycling in skeletal muscle.\",\n      \"method\": \"Recombinant GDF15 treatment in mice, β-adrenergic pathway inhibition, skeletal muscle metabolic assays, GFRAL-dependent signaling studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic endpoints with defined GFRAL-β-adrenergic axis in a high-impact peer-reviewed study\",\n      \"pmids\": [\"37380764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 expression is regulated by the integrated stress response (ISR) and is induced in selected tissues by sustained high-fat feeding or dietary amino acid imbalance. Pharmacological GDF15 administration can trigger conditioned taste aversion, suggesting an aversive signaling mechanism.\",\n      \"method\": \"Mouse dietary models, conditioned taste aversion testing, tissue-specific GDF15 expression analysis, ISR pathway studies\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal experiments in mice and humans with mechanistic pathway identification\",\n      \"pmids\": [\"30639358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GDF15 (NAG-1/hNAG-1) overexpression in transgenic mice increases thermogenic gene expression (UCP1, PGC1α, etc.) in brown adipose tissue and lipolytic gene expression (Adrb3, ATGL, HSL) in both white and brown adipose tissue, increasing energy expenditure and reducing obesity without reducing food intake.\",\n      \"method\": \"Transgenic mouse overexpression, gene expression profiling, xenograft model in obese mice\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with defined gene expression changes; single lab\",\n      \"pmids\": [\"24531647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARRB1 (β-Arrestin1) interacts with the GDF15 precursor (pro-GDF15) and facilitates its transportation to the Golgi apparatus for cleavage and maturation. Loss of ARRB1 impairs GDF15 maturation and processing.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, Arrb1 knockout mice, pro-GDF15 overexpression rescue experiments\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP demonstrating interaction plus functional rescue in KO mice, single lab\",\n      \"pmids\": [\"31857195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF15 promotes generation of peripherally derived inducible Treg cells and enhances suppressive function of natural Treg cells by interacting with CD48 on T cells, thereby downregulating STUB1 (an E3 ligase that mediates FOXP3 protein degradation), leading to immunosuppression in hepatocellular carcinoma.\",\n      \"method\": \"Co-immunoprecipitation, flow cytometry, RNA sequencing, mass spectrometry, ChIP, Gdf15-/- mice, GFP transgenic mice\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying CD48 as a GDF15 receptor in immune cells; single lab\",\n      \"pmids\": [\"34489334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Notch4 signaling in regulatory T cells induces GDF15 expression via Wnt pathway activation, and Wnt-induced GDF15 expression in Treg cells activates group 2 innate lymphoid cells (ILC2s) to promote airway inflammation in asthma.\",\n      \"method\": \"Notch4 overexpression/deletion, Wnt pathway inhibition, ILC2 activation assays, human Treg cell studies\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological manipulation with defined downstream cellular phenotype; single lab\",\n      \"pmids\": [\"32929274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AMPK activation in mouse liver (via AICAR, R419, or direct AMPK activator A769662) induces GDF15 expression and secretion, suppressing food intake. This effect is attenuated in AMPKβ1-deficient mice. A769662-induced GDF15 expression is independent of ER stress, demonstrating a direct AMPK-GDF15 regulatory axis.\",\n      \"method\": \"AMPKβ1 knockout mice, pharmacological AMPK activators, liver GDF15 expression and circulating GDF15 measurements, food intake monitoring\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple AMPK activators and KO mice with defined pathway, single lab\",\n      \"pmids\": [\"33337559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNOT6L deadenylase controls hepatic Gdf15 mRNA stability; inhibition of CNOT6L stabilizes hepatic Gdf15 mRNA, increases serum GDF15, which suppresses appetite via hindbrain activation.\",\n      \"method\": \"CNOT6L inhibition (genetic and pharmacological), mRNA stability assays, serum GDF15 measurement, food intake and metabolic profiling\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanism of mRNA decay controlling GDF15 levels with functional metabolic readouts; single lab\",\n      \"pmids\": [\"35385705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of GDF15 shows the protein is not suitable for conventional Fc fusion at the carboxyl terminus; structure-guided design was used to generate Fc fusion molecules with extended half-life. GDF15 delays gastric emptying and activates area postrema neurons.\",\n      \"method\": \"Crystal structure determination, structure-guided protein engineering, area postrema neuron activation assays, gastric emptying measurements\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation; single lab\",\n      \"pmids\": [\"29046435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GDF15 promotes proliferation of cervical cancer cells via phosphorylation of AKT1 and Erk1/2 through direct binding to and forming a complex with ErbB2 (HER2). C-Myc trans-activates GDF15 expression by binding E-box motifs in the GDF15 promoter, creating a positive feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, western blotting, ErbB2 inhibitor treatment, chromatin immunoprecipitation, in vivo tumor formation assay\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP identifying ErbB2 as receptor plus ChIP for transcriptional regulation; single lab\",\n      \"pmids\": [\"29636108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GDF15 promotes colorectal cancer EMT and metastasis by binding to TGF-β receptors to activate Smad2 and Smad3 signaling pathways.\",\n      \"method\": \"Co-immunoprecipitation, western blotting, in vitro migration/invasion assays, in vivo metastasis model, Smad2/3 phosphorylation analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, potential TGF-β contamination caveat (see PMID 29161287), mechanism via Smad activation\",\n      \"pmids\": [\"26497212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 activates AMPK and inhibits gluconeogenesis and liver fibrosis by attenuating the TGF-β1/SMAD3 pathway. In Gdf15-/- mice, elevated TGF-β1/SMAD3 pathway activity was responsible for deactivating AMPK and upregulating gluconeogenesis/fibrosis; pharmacological inhibition of SMAD3 phosphorylation in Gdf15-/- mice rescued these metabolic defects, suggesting these effects are independent of GFRAL.\",\n      \"method\": \"Gdf15-/- mice, recombinant GDF15 treatment in primary hepatocytes, SMAD3 inhibitor pharmacology, phospho-AMPK and phospho-SMAD3 western blotting\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with pharmacological rescue and in vitro validation; single lab\",\n      \"pmids\": [\"38176644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRP induces GDF15 transcription in endothelial cells through p53 recruitment to p53 binding sites in the GDF15 promoter, as demonstrated by chromatin immunoprecipitation assay.\",\n      \"method\": \"Dual-luciferase reporter assays, chromatin immunoprecipitation (ChIP), CRP plasmid transfection in human aortic endothelial cells\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay demonstrating p53-mediated transcriptional activation; single lab\",\n      \"pmids\": [\"29967567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 (NAG-1) nuclear localization signal (NLS) peptide competitive inhibition blocks NAG-1 translocation to the nucleus; accumulation of NAG-1 in the cytoplasm decreases mitochondrial membrane potential and induces apoptosis.\",\n      \"method\": \"NLS peptide transfection, subcellular fractionation, mitochondrial membrane potential assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single method approach with indirect mechanistic inference\",\n      \"pmids\": [\"31474335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Metformin activates AMPK in liver and skeletal muscle in a GDF15-dependent manner independently of GFRAL. A positive feedback loop exists where AMPK activation increases GDF15 levels, which in turn sustains AMPK activation. This effect is lost in Gdf15-/- mice.\",\n      \"method\": \"Gdf15-/- mice, cultured hepatocytes and myotubes, Gdf15 knockdown, low-dose metformin treatment, AMPK activity measurements\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice plus cell culture knockdown with defined molecular pathway; single lab\",\n      \"pmids\": [\"36435271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 enhances leptin-induced body weight and adiposity reduction in HFD obese mice through synergistic activation of hindbrain neurons. GFRAL-expressing neurons and LepR-expressing neurons show extensive connectivity in the hindbrain, and LepR knockdown in the NTS reduces GDF15-mediated activation of area postrema neurons.\",\n      \"method\": \"Combined GDF15 and leptin infusion in HFD mice, ob/ob mice (leptin-deficient), competitive leptin antagonist, hindbrain neuron activation measurement, LepR NTS-specific knockdown\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic tools with defined neuronal circuit interactions; single lab\",\n      \"pmids\": [\"37433299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 induces apoptosis in A549 lung cancer cells through activation of caspase-9 and caspase-3 and inhibition of ERK1/2 and p38 phosphorylation, and these effects depend on TGFBR2 expression—silencing TGFBR2 abolishes GDF15-induced cytotoxicity.\",\n      \"method\": \"GDF15 overexpression, TGFBR2 siRNA knockdown, annexin V/PI flow cytometry, caspase activity assays, western blotting\",\n      \"journal\": \"Cell biochemistry and function\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab with potential TGF-β contamination caveat, single cell line model\",\n      \"pmids\": [\"31172564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 reduces liver fibrosis through metabolic reprogramming of macrophages to acquire an oxidative phosphorylation-dependent anti-inflammatory phenotype. Adoptive transfer of GDF15-preprogrammed macrophages attenuates liver fibrosis.\",\n      \"method\": \"Gdf15 knockout mice, AAV8-mediated GDF15 overexpression, recombinant GDF15 treatment, macrophage metabolic profiling, adoptive transfer experiments\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple tools including KO, overexpression, adoptive transfer with defined metabolic mechanism; single lab\",\n      \"pmids\": [\"37499753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Recombinant GDF15 stimulates α-smooth muscle actin (αSMA) expression in normal human lung fibroblasts through the activin receptor-like kinase 5 (ALK5) receptor, promoting fibroblast differentiation.\",\n      \"method\": \"Recombinant GDF15 treatment of fibroblasts, ALK5 inhibitor, αSMA western blotting and immunofluorescence\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological inhibitor only to identify receptor\",\n      \"pmids\": [\"35993367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 secretion from brown adipocytes is induced by norepinephrine and cAMP through protein kinase A (PKA)-mediated mechanisms, and requires an active FGF21/β-klotho pathway. GDF15 released by brown adipocytes targets macrophages and downregulates proinflammatory gene expression.\",\n      \"method\": \"Brown adipocyte cell cultures, FGF21/β-klotho invalidation models, PKA pathway inhibitors, macrophage co-culture (RAW264.7), gene expression analysis\",\n      \"journal\": \"Obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple cell culture models with pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"31411815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Single nuclei RNA-seq of the area postrema and NTS identified a single population of Gfral- and Ret-positive excitatory neurons as the primary site of GDF15 action. Systemic GDF15 treatment produced cell-type-specific transcriptome alterations in these neurons and in surrounding glia.\",\n      \"method\": \"Single nuclei RNA sequencing (~35,000 nuclei), Seurat cell-type clustering, rat area postrema/NTS micropunches after GDF15 injection\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — high-resolution transcriptomic characterization of GDF15-responding neurons with defined receptor co-expression\",\n      \"pmids\": [\"34942400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 and semaglutide reduce food intake and body weight through distinct mechanisms: semaglutide amplifies the satiating effect of ingested food and CCK, reduces feeding motivation, and inhibits AgRP neuron activity; whereas GDF15 induces visceral malaise but does not affect feeding motivation, CCK signaling, or AgRP neuron activity.\",\n      \"method\": \"Rat pharma-behavioral experiments, progressive ratio operant paradigm, pica/kaolin assay, conditioned aversion testing, fiber photometry of AgRP-Cre mice\",\n      \"journal\": \"Diabetes, obesity & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple behavioral and neural circuit methods distinguishing GDF15 mechanism from GLP-1R agonist; single lab\",\n      \"pmids\": [\"35129264\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GDF15 is a stress-induced secreted cytokine (TGFβ superfamily) that signals primarily through a brainstem-restricted heterodimeric receptor complex of GFRAL and co-receptor RET, expressed exclusively in area postrema and NTS neurons, to suppress food intake and induce conditioned aversion; peripheral effects include a sympathetic-adrenergic lipolytic axis in adipose tissue and β-adrenergic-dependent enhancement of skeletal muscle energy expenditure; GDF15 expression is transcriptionally regulated by p53, integrated stress response, and AMPK, and post-translationally by ARRB1-facilitated Golgi transport for pro-protein cleavage; additional context-dependent signaling occurs via ErbB2, CD48 (in immune cells), ALK5 (in fibroblasts), and TGF-β1/SMAD3 pathway modulation, though the GFRAL-RET axis in the hindbrain remains the canonical and best-established signaling pathway.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"GDF15 (then called MIC-1) is a divergent member of the TGF-β superfamily. It is synthesized as a propeptide, undergoes proteolytic cleavage, and is secreted as a cysteine-rich disulfide-linked 25 kDa dimer. In macrophages, its expression is upregulated by IL-1β, TNF-α, IL-2, M-CSF, and TGF-β, and purified recombinant MIC-1 inhibits LPS-induced macrophage TNF-α production, indicating an autocrine regulatory role in limiting macrophage activation.\",\n      \"method\": \"Subtraction cloning, CHO-cell expression with propeptide cleavage verification, purification of recombinant protein, functional TNF-α inhibition assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning paper with biochemical characterization, expression studies, and direct functional assay; foundational study replicated across the field\",\n      \"pmids\": [\"9326641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GDF15 (PTGF-β) is a direct transcriptional target of p53; the GDF15 promoter contains two p53-binding site motifs, one of which is essential for p53-mediated induction and specifically binds recombinant p53 in gel-shift assays. GDF15 overexpression induces both G1 cell-cycle arrest and apoptosis in breast cancer cells, establishing it as a downstream mediator of p53-dependent growth arrest.\",\n      \"method\": \"Promoter-luciferase reporter assay, electrophoretic mobility shift assay (EMSA) with recombinant p53, adenoviral overexpression, flow cytometry for cell-cycle and apoptosis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding of p53 to GDF15 promoter shown by EMSA, functional consequence confirmed by adenoviral overexpression with defined phenotype\",\n      \"pmids\": [\"10777512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"GDF15 (NAG-1) expression is induced by NSAID treatment (cyclooxygenase inhibitors) through COX-independent mechanisms in colorectal cancer cells, and forced GDF15 overexpression increases basal apoptosis and reduces tumorigenicity in nude mice, demonstrating a proapoptotic and antitumorigenic function.\",\n      \"method\": \"Subtractive hybridization, stable transfection, soft-agar colony assay, xenograft tumor model in nude mice\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (transfection, in vitro growth assay, in vivo xenograft) supporting antitumorigenic function\",\n      \"pmids\": [\"11259636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GDF15 is induced in cardiomyocytes under ischemia/reperfusion (I/R) via NO-peroxynitrite-dependent signaling. Gdf15-knockout mice develop larger infarct sizes and more cardiomyocyte apoptosis after I/R than wild-type littermates. Recombinant GDF15 protects cultured cardiomyocytes from apoptosis during simulated I/R, and this protective effect is abolished by PI3K inhibitors and dominant-negative Akt1, placing GDF15 upstream of PI3K-Akt1 survival signaling.\",\n      \"method\": \"Gdf15 gene-targeted (knockout) mice with coronary artery ligation model, recombinant GDF15 treatment, histone ELISA/TUNEL/annexin-V FACS for apoptosis, PI3K inhibitor pharmacology, adenoviral dominant-negative Akt1\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO model with defined phenotype plus pharmacological and dominant-negative mechanistic dissection, replicated with recombinant protein\",\n      \"pmids\": [\"16397141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Elevated circulating MIC-1/GDF15 produced by tumors causes anorexia and weight loss by acting centrally; in xenograft models, antibody neutralization of MIC-1 reverses weight loss. GDF15 mediates its effects via hypothalamic TGF-β receptor II, and downstream activation of ERK1/2, STAT3, and modulation of NPY and POMC neuropeptides.\",\n      \"method\": \"Prostate cancer xenograft mouse model, anti-MIC-1 antibody neutralization, hypothalamic signaling analysis (ERK1/2, STAT3), neuropeptide measurement\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antibody neutralization reversal in vivo combined with defined downstream signaling pathway identification; replicated across multiple cancer models\",\n      \"pmids\": [\"17982462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"During erythroblast maturation, GDF15 expression and secretion increase substantially. In β-thalassemia patients, markedly elevated serum GDF15 suppresses hepcidin mRNA expression in primary human hepatocytes; depletion of GDF15 from thalassemia patient serum reverses hepcidin suppression, demonstrating that GDF15 is a key erythroid regulator that suppresses hepcidin and contributes to iron overload.\",\n      \"method\": \"Erythroblast transcriptome profiling, GDF15 ELISA in patient serum, primary hepatocyte culture with patient serum, GDF15 immunodepletion with functional rescue\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — immunodepletion experiment directly demonstrates GDF15 causality for hepcidin suppression; supported by large patient cohort and primary cell assays\",\n      \"pmids\": [\"17721544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In transgenic mice ubiquitously expressing human GDF15 (NAG-1), GDF15 prevents obesity by increasing expression of thermogenic genes (UCP1, PGC1α, Dio2, Cox8b) in brown adipose tissue and lipolytic genes (Adrb3, ATGL, HSL) in both white and brown adipose tissue, leading to higher energy expenditure without reducing food intake.\",\n      \"method\": \"Transgenic mouse model, xenograft model (melanoma cells secreting GDF15), thermogenic and lipolytic gene expression analysis, metabolic phenotyping (glucose tolerance, insulin levels, energy expenditure)\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic and xenograft models with detailed mechanistic gene expression analysis; consistent results across two experimental approaches\",\n      \"pmids\": [\"24531647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GDF15 produced in skeletal muscle with mitochondrial dysfunction (due to Crif1 deficiency activating UPRmt) acts as a myomitokine to regulate systemic energy homeostasis; elevated GDF15 secretion in muscle-specific Crif1-KO mice protects against obesity and improves insulin sensitivity. Recombinant GDF15 in ob/ob mice reduces body weight through elevated oxidative metabolism and lipid mobilization in liver, muscle, and adipose tissue.\",\n      \"method\": \"Muscle-specific Crif1-KO mouse model, recombinant GDF15 administration in ob/ob mice, metabolic phenotyping, oxidative metabolism assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic muscle-specific KO with defined metabolic phenotype, corroborated by recombinant GDF15 treatment experiments\",\n      \"pmids\": [\"27986797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GFRAL (GDNF family receptor α-like) is the cognate receptor for GDF15 in the hindbrain. GDF15 binds GFRAL with high affinity; Gfral-knockout mice are refractory to GDF15-induced reductions in food intake, body weight, and glucose parameters. GFRAL mRNA is expressed exclusively in neurons of the area postrema and nucleus of the solitary tract. GDF15-induced cell signaling requires interaction of GFRAL with the co-receptor RET tyrosine kinase.\",\n      \"method\": \"Receptor binding assay (high-affinity binding), Gfral-knockout mice with recombinant GDF15 treatment, GFRAL monoclonal antibody blockade in rats, immunohistochemistry/in situ hybridization for receptor localization, RET co-receptor signaling studies\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple independent groups simultaneously identified GFRAL using binding assays, genetic KO, and antibody blockade; findings replicated across four independent papers in the same issue\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28953886\", \"28846099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDF15 activates GFRAL-expressing neurons exclusively in the area postrema and nucleus tractus solitarius of the brainstem, which then activate neurons in the parabrachial nucleus and central amygdala (the 'emergency circuit'). Gfral-knockout mice are hyperphagic under stress conditions and resistant to chemotherapy-induced anorexia and weight loss, establishing this as a non-homeostatic neural circuit.\",\n      \"method\": \"Gfral-knockout mouse model with chemotherapy-induced anorexia model, neuronal activation mapping (c-Fos), circuit tracing, metabolic phenotyping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined behavioral and circuit-level phenotype using multiple stress paradigms\",\n      \"pmids\": [\"28953886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GDF15 promotes proliferation of cervical cancer cells by binding to ErbB2 (HER2) in a protein complex, leading to phosphorylation of AKT1 and Erk1/2 and upregulation of CyclinD1 and CyclinE1 while downregulating p21. C-myc trans-activates GDF15 expression by binding E-box motifs in the GDF15 promoter, creating a positive feedback loop.\",\n      \"method\": \"Immunoprecipitation to show GDF15-ErbB2 complex, western blotting for phospho-AKT1 and phospho-Erk1/2, chromatin immunoprecipitation (ChIP) for C-myc binding to GDF15 promoter, flow cytometry for cell cycle, xenograft tumor formation assay\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and ChIP provide mechanistic evidence but ErbB2 as a GDF15 receptor is a single-lab finding not widely replicated\",\n      \"pmids\": [\"29636108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARRB1 (β-Arrestin1) interacts directly with pro-GDF15 and facilitates its transport to the Golgi apparatus for proteolytic cleavage and maturation into secreted GDF15. Arrb1-deficient mice have impaired GDF15 maturation and develop accelerated steatohepatitis; re-expression of Arrb1 or supplementation with recombinant GDF15 rescues the phenotype.\",\n      \"method\": \"Co-immunoprecipitation of ARRB1 with pro-GDF15, Arrb1-knockout mouse models (HFD and MCD diet), recombinant GDF15 rescue experiment, subcellular fractionation/Golgi localization\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus KO rescue provides mechanistic evidence; Golgi transport role supported by genetic and biochemical data from single lab\",\n      \"pmids\": [\"31857195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Metformin induces GDF15 expression and secretion from hepatocytes by activating ATF4 and CHOP (DDIT3) transcription factors as part of the integrated stress response. In wild-type mice on high-fat diet, oral metformin increases serum GDF15 and reduces food intake and body mass; these effects are absent in GDF15-null mice, demonstrating that GDF15 is required for metformin's effects on appetite and body weight.\",\n      \"method\": \"Unbiased hepatocyte transcriptomics, human serum proteomics, primary mouse hepatocyte culture, GDF15-null mice with metformin treatment, ATF4/CHOP mechanistic studies\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — GDF15-null genetic model with defined phenotype plus mechanistic transcription factor identification in primary cells\",\n      \"pmids\": [\"32694673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 expression is regulated by the integrated stress response (ISR) in selected tissues during sustained high-fat feeding or dietary amino acid imbalance. Pharmacological GDF15 administration to mice triggers conditioned taste aversion, suggesting that GDF15 induces aversive/nausea-like responses rather than classical satiety signaling.\",\n      \"method\": \"Mouse dietary stress models (high-fat and amino acid imbalance diets), ISR pathway analysis in tissues, conditioned taste aversion behavioral assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple dietary models with ISR pathway analysis plus defined behavioral phenotype (conditioned taste aversion) establishing mechanistic basis\",\n      \"pmids\": [\"30639358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 mediates the weight loss effects of metformin in vivo; in two independent randomized controlled clinical trials, metformin increases circulating GDF15. In mice, GDF15 is expressed predominantly in the distal intestine and kidney in response to metformin, and Gdf15-knockout or GFRAL-antagonist antibody-treated mice fail to show metformin-induced body-weight reduction, while glucose-lowering effects are preserved.\",\n      \"method\": \"Randomized controlled clinical trials (two independent), Gdf15-knockout mice, GFRAL antagonist antibody in obese mice, tissue-specific GDF15 expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two RCTs plus genetic KO and pharmacological antagonism converge on the same mechanism; GDF15-independent glucose lowering also established\",\n      \"pmids\": [\"31875646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Brown adipocytes release GDF15 in response to thermogenic activation via norepinephrine/cAMP through protein kinase A (PKA)-mediated mechanisms, and this release requires the active FGF21-β-klotho signaling pathway. GDF15 released by brown adipocytes targets macrophages and downregulates proinflammatory gene expression.\",\n      \"method\": \"Cold exposure of mice, norepinephrine/cAMP treatment of brown adipocyte cultures, PKA inhibitor experiments, FGF21/β-klotho invalidation cell models, RAW264.7 macrophage co-culture/conditioned medium experiments\",\n      \"journal\": \"Obesity (Silver Spring)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro mechanistic dissection with PKA and FGF21 pathway validated, anti-inflammatory targeting of macrophages shown, single lab\",\n      \"pmids\": [\"31411815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Antibody-mediated inhibition of GFRAL (monoclonal antibody 3P10) blocks GDF15-driven RET co-receptor recruitment and signaling on brainstem neurons. GDF15-GFRAL-RET pathway activation induces lipid oxidation genes in adipose tissue, and peripheral sympathetic nervous system and adipose triglyceride lipase (ATGL) are required for GDF15-induced lipolysis and adipose/muscle mass loss, establishing a peripheral sympathetic-lipolytic axis downstream of GFRAL-RET.\",\n      \"method\": \"GFRAL antagonist monoclonal antibody (3P10) in tumor-bearing mice, chemical sympathectomy, ATGL-knockout mice, adipose tissue gene expression analysis, cancer cachexia mouse models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches identifying sympathetic axis and ATGL as mediators of GDF15-induced peripheral lipolysis\",\n      \"pmids\": [\"32661391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF15 promotes immunosuppression in hepatocellular carcinoma by interacting with CD48 on T cells (identified as a GDF15 receptor in the immune system). This interaction downregulates STUB1, an E3 ubiquitin ligase that mediates FOXP3 degradation, thereby stabilizing FOXP3 and enhancing generation and suppressive function of regulatory T cells.\",\n      \"method\": \"Co-immunoprecipitation of GDF15 with CD48, mass spectrometry, CyTOF immune profiling, Gdf15-knockout mouse orthotopic HCC models, RNA sequencing, ChIP, OT-I transgenic mice, flow cytometry for FOXP3 and Treg function\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and MS identify CD48 interaction, STUB1/FOXP3 mechanism supported by multiple methods, but CD48 as GDF15 receptor is a single-lab finding requiring independent replication\",\n      \"pmids\": [\"34489334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF15 induces visceral malaise (conditioned taste aversion, kaolin intake) but does not reduce feeding motivation or amplify gastrointestinal satiation signals (CCK or ingested food), in contrast to semaglutide. GDF15 does not modulate AgRP neuron calcium signaling, while semaglutide does; the two agents act through largely distinct, additive neural mechanisms to reduce food intake.\",\n      \"method\": \"Rat pharmaco-behavioral experiments (CCK potentiation, progressive ratio operant paradigm, kaolin intake, conditioned affective food aversion), fibre photometry in AgRP-Cre mice\",\n      \"journal\": \"Diabetes, obesity & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal behavioral and photometry methods dissecting GDF15 mechanism vs. GLP-1 agonist, single lab\",\n      \"pmids\": [\"35129264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRP induces GDF15 transcription in human aortic endothelial cells via p53 recruitment to two p53-binding sites in the GDF15 promoter, as confirmed by ChIP and dual-luciferase reporter assays, linking inflammatory CRP signaling to p53-dependent GDF15 expression.\",\n      \"method\": \"CRP treatment of human aortic endothelial cells, dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) for p53 at GDF15 promoter\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic evidence (ChIP + reporter) for CRP-p53-GDF15 axis in primary endothelial cells, single lab\",\n      \"pmids\": [\"29967567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AMPK (specifically β1-containing complexes) mediates energetic stress-induced hepatic GDF15 expression. Direct AMPK β1 activation (A769662) increases hepatic Gdf15 expression and circulating GDF15 independently of ER stress. Effects of AICAR, R419, and A769662 on GDF15 are all attenuated in AMPKβ1-knockout mice, while CHOP (downstream of ER stress) is not required for A769662-induced GDF15.\",\n      \"method\": \"AMPKβ1-knockout and CHOP-knockout mice, three pharmacological AMPK activators (AICAR, R419, A769662), hepatic adenine nucleotide and GDF15 measurements, food intake assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three distinct AMPK activators plus two genetic KO models with orthogonal results dissecting AMPK vs. ER stress pathway\",\n      \"pmids\": [\"33337559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF15 acts via the GFRAL-RET receptor complex in area postrema/NTS excitatory neurons; single-nuclei RNA sequencing identified ~600 cell-type-specific transcriptomic changes in AP/NTS neurons and glia after systemic GDF15 treatment, mapping downstream signaling pathways specifically in Gfral/Ret-positive excitatory neurons.\",\n      \"method\": \"Single-nuclei RNA sequencing (snRNAseq) of rat AP/NTS micropunches after GDF15 injection, Seurat-based cell-type clustering, differential gene expression\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific transcriptomic profiling at single-nucleus resolution identifying downstream signaling, single lab\",\n      \"pmids\": [\"34942400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Notch4 signaling on lung Treg cells upregulates GDF15 expression (via Wnt pathway), and this Treg-derived GDF15 activates group 2 innate lymphoid cells (ILC2s) to create a feed-forward loop promoting airway inflammation in asthma.\",\n      \"method\": \"Notch4-conditional mouse models, Wnt pathway inhibitor experiments, ILC2 activation assays, human asthma patient Treg analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse models with defined inflammatory phenotype and ILC2 activation assay, but GDF15's direct receptor on ILC2s not characterized\",\n      \"pmids\": [\"32929274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNOT6L deadenylase controls the stability of hepatic Gdf15 mRNA; CNOT6L inhibition stabilizes Gdf15 mRNA, increasing serum GDF15 protein levels, which then suppresses appetite via hindbrain activation.\",\n      \"method\": \"CNOT6L genetic inhibition models, mRNA stability assays, serum GDF15 ELISA, food intake measurement, small-molecule CNOT6L inhibitor screening\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological manipulation of mRNA stability with defined protein output and physiological consequence, single lab\",\n      \"pmids\": [\"35385705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A positive feedback loop exists between AMPK and GDF15 in the context of metformin action: metformin activates AMPK, which increases GDF15; GDF15 in turn sustains full AMPK activation in liver and skeletal muscle independently of the CNS/GFRAL. Gdf15-knockout mice show blunted AMPK activation in response to metformin, and Gdf15 knockdown in cultured hepatocytes and myotubes reduces metformin-induced AMPK activation.\",\n      \"method\": \"Gdf15-knockout mice, Gdf15 siRNA knockdown in hepatocytes/myotubes, metformin treatment, AMPK phosphorylation western blotting, glucose tolerance testing\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and siRNA knockdown with defined signaling phenotype establishing AMPK-GDF15 feedback, single lab\",\n      \"pmids\": [\"36435271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 knockdown decreases SLC7A11 (system Xc- transporter) expression, promoting erastin-induced ferroptosis in gastric cancer MGC803 cells. GDF15 knockdown reduces intracellular GSH and increases lipid ROS levels, and blocks the erastin-induced upregulation of SLC7A11, indicating GDF15 supports ferroptosis resistance via SLC7A11.\",\n      \"method\": \"GDF15 siRNA knockdown, CCK-8 cell viability assay, qRT-PCR and western blotting for SLC7A11, glutamate/GSH measurement, lipid ROS detection\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single knockdown approach without rescue or upstream mechanistic detail connecting GDF15 to SLC7A11 regulation\",\n      \"pmids\": [\"32209255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 overexpression in transgenic mice inhibits HFD/STZ-induced non-alcoholic steatohepatitis by suppressing oxidative stress-mediated mitochondrial damage and double-strand DNA release into the cytosol, thereby blocking AIM2 inflammasome activation and reducing IL-18 and IL-1β secretion. This effect is independent of reduced food intake.\",\n      \"method\": \"NAG-1/GDF15 transgenic mice on HFD, free fatty acid-treated hepatocyte steatosis models, GDF15 siRNA knockdown, oxidative stress markers, dsDNA cytosolic release assay, AIM2 inflammasome activation assay (IL-18/IL-1β ELISA)\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic and knockdown models with defined inflammasome mechanistic pathway, corroborated in both in vivo and in vitro systems\",\n      \"pmids\": [\"35504134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 NAG-1 inhibits HFD/STZ-induced diabetic nephropathy by inhibiting the AGE/RAGE axis and associated downstream TLR4/MyD88/NF-κB inflammatory signaling, as well as reducing adhesion molecules, in both transgenic mice and high-glucose-treated HK-2 renal tubular cells.\",\n      \"method\": \"NAG-1/GDF15 transgenic mice with HFD/STZ DN model, transcriptome analysis, recombinant GDF15 protein treatment of HK-2 cells, western blotting for AGE/RAGE, TLR4/MyD88/NF-κB pathway components\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic model with transcriptome plus in vitro recombinant protein confirmation identifying AGE/RAGE-NF-κB pathway, single lab\",\n      \"pmids\": [\"36367498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 promotes skin pigmentation by stimulating melanogenesis through MITF/tyrosinase upregulation via β-catenin signaling in melanocytes. This effect is mediated by GDF15 secreted from UV-irradiated senescent fibroblasts.\",\n      \"method\": \"GDF15 lentiviral overexpression and shRNA knockdown in fibroblasts, co-culture of melanocytes with GDF15-expressing fibroblasts, β-catenin signaling analysis, ex vivo skin culture, reconstituted human skin model\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-culture system with lentiviral gain- and loss-of-function plus β-catenin pathway placement, ex vivo validation; single lab\",\n      \"pmids\": [\"32416083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 expression in IPF lung-derived extracellular matrix is markedly elevated, and recombinant GDF15 stimulates α-smooth muscle actin (αSMA) expression in normal human lung fibroblasts through the ALK5 (TGF-β type I receptor) pathway. GDF15 neutralization in a bleomycin lung fibrosis mouse model significantly reduces fibrosis.\",\n      \"method\": \"3D spheroid fibroblast assay with IPF ECM, proteomics of IPF ECM, recombinant GDF15 stimulation with ALK5 inhibitor, αSMA expression, bleomycin lung fibrosis mouse model with GDF15 neutralizing antibody, collagen gel migration assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro ALK5 pathway dissection plus in vivo neutralization in fibrosis model, multiple assays; single lab\",\n      \"pmids\": [\"35993367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In addition to suppressing appetite via GFRAL, GDF15 counteracts adaptive thermogenesis (compensatory energy expenditure reduction) during caloric restriction. This effect requires a GFRAL-β-adrenergic receptor-dependent signaling axis that increases fatty acid oxidation and calcium futile cycling in skeletal muscle, resulting in maintained energy expenditure during weight loss.\",\n      \"method\": \"Recombinant GDF15 treatment in calorie-restricted mice, GFRAL-knockout mice, β-adrenergic blocker pharmacology, skeletal muscle fatty acid oxidation assays, calcium cycling measurements, NAFLD assessment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic GFRAL-KO and pharmacological β-adrenergic blockade converge on the same mechanism; multiple metabolic readouts in defined mouse models\",\n      \"pmids\": [\"37380764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 and leptin synergize in the hindbrain to enhance weight and adiposity loss; LepR-expressing neurons in the NTS are extensively connected with GFRAL-expressing neurons, and LepR knockdown in the NTS reduces GDF15-mediated activation of area postrema neurons, establishing that leptin receptor signaling in the hindbrain potentiates GDF15's metabolic actions.\",\n      \"method\": \"Combined GDF15 and leptin infusion in HFD mice, competitive leptin antagonist in normal mice, ob/ob mice (leptin-deficient), AAV-mediated LepR knockdown in NTS, hindbrain neuronal activation mapping\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic (ob/ob, AAV-KD) and pharmacological (leptin antagonist) approaches plus neuronal circuit mapping; single lab\",\n      \"pmids\": [\"37433299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 ameliorates liver fibrosis by reprogramming macrophage metabolic pathways toward oxidative phosphorylation, inducing an anti-inflammatory functional fate. Adoptive transfer of GDF15-preprogrammed macrophages to CCl4 fibrosis mouse models attenuates inflammation and liver fibrosis progression.\",\n      \"method\": \"Gdf15-knockout mice in CCl4 and DDC diet fibrosis models, AAV8-mediated GDF15 overexpression in hepatocytes, recombinant GDF15 treatment, CyTOF/flow cytometry for immune profiling, metabolic flux analysis of macrophages, adoptive transfer of GDF15-preprogrammed macrophages\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO, gene delivery, and adoptive transfer provide orthogonal evidence for macrophage reprogramming mechanism; single lab\",\n      \"pmids\": [\"37499753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GDF15 activates hepatic AMPK and inhibits gluconeogenesis and fibrosis by attenuating the TGF-β1/SMAD3 pathway independently of its central receptor GFRAL. Gdf15-knockout mice show reduced hepatic AMPK phosphorylation, elevated pSMAD3, increased TGF-β1, and enhanced gluconeogenesis/fibrosis. Recombinant GDF15 in primary hepatocytes reduces pSMAD3 and gluconeogenic markers, and pharmacological SMAD3 inhibition in Gdf15-KO mice rescues AMPK activity and metabolic phenotype.\",\n      \"method\": \"Gdf15-knockout mice, recombinant GDF15 in primary hepatocytes and Huh-7 cells, SMAD3 pharmacological inhibition, AMPK phosphorylation western blotting, gluconeogenic gene expression, liver fibrosis histology\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model plus recombinant protein plus pharmacological rescue identifying TGF-β1/SMAD3-AMPK axis; GFRAL-independence suggested but receptor for this peripheral effect not identified\",\n      \"pmids\": [\"38176644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cardiac stress upregulates GDF15 expression in cardiomyocytes via ISR/eIF2α phosphatase (PPP1R15A) pathway, and elevated circulating GDF15 drives weight loss and worsens cardiac function (cardiac cachexia). GDF15 blockade prevents cachexia and slows heart failure progression in a dilated cardiomyopathy mouse model.\",\n      \"method\": \"PPP1R15A-knockout mouse model with irradiation-induced dilated cardiomyopathy, cardiac GDF15 expression analysis, GDF15 blocking antibody treatment, lean mass and cardiac function measurements\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with defined cardiac phenotype plus antibody blockade demonstrating GDF15-dependent cardiac cachexia; single lab\",\n      \"pmids\": [\"39312445\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GDF15 is a stress-responsive, secreted TGF-β superfamily dimeric cytokine that signals primarily through a brainstem-restricted GFRAL-RET heterodimeric receptor complex expressed exclusively in area postrema and nucleus tractus solitarius neurons, activating downstream PI3K-Akt and sympathetic nervous system pathways to suppress appetite, induce conditioned taste aversion, and counteract adaptive thermogenesis via a GFRAL-β-adrenergic-skeletal muscle axis; it is transcriptionally induced by p53, ATF4/CHOP (integrated stress response), and AMPK, undergoes Golgi-dependent proteolytic maturation facilitated by ARRB1, and in addition to its central effects exerts peripheral actions including hepcidin suppression (contributing to iron overload in thalassemia), cardioprotection via PI3K-Akt1, macrophage metabolic reprogramming, fibroblast ALK5-dependent pro-fibrotic signaling, and SMAD3 pathway attenuation to regulate hepatic gluconeogenesis and fibrosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GDF15 is a stress-responsive secreted cytokine of the TGF-β superfamily that functions as a central regulator of energy balance by signaling through the brainstem-restricted GFRAL–RET receptor complex to suppress food intake, induce conditioned aversion, and modulate peripheral energy expenditure. GDF15 binds GFRAL, expressed exclusively in area postrema and nucleus tractus solitarius neurons, activating a circuit through the parabrachial nucleus and central amygdala that reduces feeding under stress conditions including chemotherapy and high-fat diet challenge; this pathway also mediates the weight-lowering effects of metformin [PMID:28846097, PMID:28953886, PMID:31875646]. Beyond anorexia, GDF15–GFRAL signaling engages a peripheral sympathetic–β-adrenergic axis that promotes lipolysis in adipose tissue and counteracts adaptive thermogenesis during caloric restriction by increasing fatty acid oxidation and calcium futile cycling in skeletal muscle [PMID:32661391, PMID:37380764]. GDF15 transcription is induced by p53, the integrated stress response, and AMPK activation, while its mRNA stability is controlled by the CNOT6L deadenylase and its pro-protein maturation requires ARRB1-facilitated Golgi transport [PMID:29967567, PMID:30639358, PMID:33337559, PMID:35385705, PMID:31857195].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Before the receptor was known, transgenic overexpression established that GDF15 could increase energy expenditure and thermogenic/lipolytic gene programs in adipose tissue independently of reduced food intake, pointing to peripheral metabolic effector functions.\",\n      \"evidence\": \"GDF15-overexpressing transgenic mice with adipose gene expression profiling\",\n      \"pmids\": [\"24531647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating these effects was unknown\", \"Supraphysiological overexpression may not reflect endogenous biology\", \"CNS versus peripheral site of action unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Four independent groups simultaneously identified GFRAL as the high-affinity receptor for GDF15, restricted to area postrema/NTS neurons, and showed that GFRAL deletion abolished GDF15-induced anorexia and weight loss, establishing the canonical signaling axis and its requirement for the co-receptor RET.\",\n      \"evidence\": \"Receptor binding assays, Gfral knockout mice, circuit mapping with c-Fos, crystal structure of GDF15\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28953886\", \"29046435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream intracellular signaling cascade in GFRAL neurons not fully mapped\", \"Whether GFRAL-independent receptors contribute in any context remained open\", \"Structural basis of the trimeric GDF15–GFRAL–RET complex not yet resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of p53 as a transcriptional activator of GDF15 and of ErbB2 as an alternative receptor in cancer cells expanded the regulatory and signaling landscape beyond the GFRAL axis.\",\n      \"evidence\": \"ChIP showing p53 binding to GDF15 promoter in endothelial cells; co-IP identifying GDF15–ErbB2 complex in cervical cancer cells\",\n      \"pmids\": [\"29967567\", \"29636108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ErbB2 interaction demonstrated in a single cancer cell context\", \"Relative physiological importance of ErbB2 versus GFRAL signaling unresolved\", \"Whether p53-mediated GDF15 induction is universal or tissue-specific unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple studies established that GDF15 expression is controlled by the integrated stress response and AMPK, that it induces conditioned taste aversion, and that its pro-protein maturation depends on ARRB1-facilitated Golgi transport, building a comprehensive picture of transcriptional, post-translational, and behavioral regulation.\",\n      \"evidence\": \"Mouse dietary models with ISR pathway analysis; AMPK activators in AMPKβ1-KO mice; Arrb1 knockout with subcellular fractionation; conditioned taste aversion testing\",\n      \"pmids\": [\"30639358\", \"33337559\", \"31857195\", \"31411815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise ISR transcription factors binding the GDF15 promoter not fully identified\", \"ARRB1 interaction validated by co-IP but structural details unknown\", \"Whether aversion and anorexia are separable endpoints of GFRAL signaling remained unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Metformin's weight-lowering effect was shown to require GDF15–GFRAL signaling, while its glucose-lowering effect was GDF15-independent, establishing GDF15 as the critical mediator of a widely used drug's anorectic action.\",\n      \"evidence\": \"Gdf15 knockout mice, GFRAL-antagonist antibody, human RCT with circulating GDF15 measurements\",\n      \"pmids\": [\"31875646\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other biguanides share this mechanism unknown\", \"Tissue source of metformin-induced GDF15 (intestine versus kidney) not definitively resolved\", \"Long-term compensatory mechanisms not assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The peripheral effector arm of GDF15 was delineated: GFRAL-RET signaling engages sympathetic nerves to drive adipose lipolysis through adipose triglyceride lipase, demonstrating a weight loss mechanism independent of reduced food intake.\",\n      \"evidence\": \"Anti-GFRAL antibody blocking RET interaction, chemical sympathectomy, ATGL-knockout mice\",\n      \"pmids\": [\"32661391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the sympathetic signal originates from brainstem GFRAL neurons or involves intermediate relay nuclei unresolved\", \"Direct innervation patterns not traced\", \"Contribution of lipolysis versus thermogenesis to net weight loss not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Single-nuclei transcriptomics pinpointed a single Gfral+/Ret+ excitatory neuron population in area postrema/NTS as the primary cellular target, and immune studies identified CD48 as an alternative GDF15 receptor on T cells mediating Treg-dependent immunosuppression.\",\n      \"evidence\": \"snRNA-seq of ~35,000 nuclei from rat AP/NTS; co-IP, flow cytometry, and Gdf15−/− mice in HCC immune context\",\n      \"pmids\": [\"34942400\", \"34489334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CD48 interaction not yet independently replicated\", \"Downstream signaling from CD48 in T cells not fully mapped\", \"Whether glial transcriptomic changes are functionally required unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-transcriptional control of GDF15 was established via CNOT6L-mediated mRNA deadenylation in liver, and behavioral dissection showed that GDF15 reduces feeding through visceral malaise/aversion rather than satiation, mechanistically distinguishing it from GLP-1 receptor agonists.\",\n      \"evidence\": \"CNOT6L genetic/pharmacological inhibition with mRNA stability assays; rat behavioral paradigms including pica, progressive ratio, and AgRP fiber photometry\",\n      \"pmids\": [\"35385705\", \"35129264\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CNOT6L-GDF15 axis operates in tissues beyond liver unknown\", \"Aversion versus nausea distinction at the circuit level not resolved\", \"Whether chronic GDF15 exposure leads to aversion tolerance not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"GDF15 was shown to counteract adaptive thermogenesis during caloric restriction via a GFRAL–β-adrenergic axis that increases skeletal muscle fatty acid oxidation and calcium futile cycling, and to synergize with leptin through interconnected hindbrain LepR and GFRAL neuron populations.\",\n      \"evidence\": \"Recombinant GDF15 with β-adrenergic inhibition in mice; combined GDF15/leptin infusion with NTS-specific LepR knockdown\",\n      \"pmids\": [\"37380764\", \"37433299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the β-adrenergic-to-muscle relay not fully defined\", \"Whether GDF15–leptin synergy is relevant at endogenous hormone levels unknown\", \"Calcium futile cycling pathway components downstream of β-adrenergic activation not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the GDF15–GFRAL–RET ternary complex, the relative physiological importance of non-GFRAL receptors (CD48, ErbB2, ALK5, TGFBR2), the circuit logic connecting brainstem GFRAL neurons to sympathetic outflow, and whether chronic GDF15 exposure in humans produces sustained weight loss or tolerance through aversion habituation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ternary complex structure available\", \"Non-GFRAL receptor interactions each reported by single labs without independent replication\", \"Human long-term efficacy and tolerability data from GDF15-based therapeutics incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 4, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 10, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3, 5, 12]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 4, 8, 13, 19]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 4, 6, 10, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 9, 21]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 24, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GFRAL\",\n      \"RET\",\n      \"ARRB1\",\n      \"CD48\",\n      \"ERBB2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"GDF15 is a stress-responsive, secreted TGF-β superfamily cytokine that functions as a central regulator of energy balance, appetite, and tissue-protective responses across multiple organ systems. It is synthesized as a propeptide, undergoes proteolytic maturation facilitated by ARRB1-mediated Golgi transport, and is secreted as a disulfide-linked dimer whose transcription is driven by p53, ATF4/CHOP (integrated stress response), and AMPKβ1 [PMID:9326641, PMID:10777512, PMID:32694673, PMID:33337559, PMID:31857195]. Circulating GDF15 signals through the brainstem-restricted GFRAL–RET receptor tyrosine kinase complex in area postrema/nucleus tractus solitarius neurons to suppress food intake via conditioned aversion, activate sympathetic outflow that drives peripheral lipolysis through ATGL, and counteract adaptive thermogenesis via β-adrenergic–skeletal muscle fatty acid oxidation and calcium futile cycling [PMID:28846097, PMID:28953886, PMID:32661391, PMID:37380764, PMID:30639358]. Beyond its central metabolic actions, GDF15 exerts GFRAL-independent peripheral effects including cardioprotection via PI3K-Akt1 signaling, suppression of hepatic gluconeogenesis and fibrosis through SMAD3 pathway attenuation, macrophage metabolic reprogramming toward oxidative phosphorylation, hepcidin suppression contributing to iron overload in β-thalassemia, and pro-fibrotic ALK5-dependent signaling in lung fibroblasts [PMID:16397141, PMID:38176644, PMID:37499753, PMID:17721544, PMID:35993367].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying GDF15 as a new TGF-β superfamily member secreted as a disulfide-linked dimer from macrophages established its biochemical identity and initial autocrine anti-inflammatory function.\",\n      \"evidence\": \"Subtraction cloning from activated macrophages, recombinant protein purification from CHO cells, and functional TNF-α inhibition assay\",\n      \"pmids\": [\"9326641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown\", \"In vivo relevance of macrophage regulation not tested\", \"Signaling pathway downstream of GDF15 not identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that p53 directly binds and transactivates the GDF15 promoter linked GDF15 to the tumor suppressor network and explained its stress-inducible expression pattern.\",\n      \"evidence\": \"EMSA with recombinant p53, promoter-luciferase reporters, and adenoviral overexpression causing G1 arrest and apoptosis in breast cancer cells\",\n      \"pmids\": [\"10777512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other stress-responsive transcription factors not yet mapped\", \"Whether p53-GDF15 axis operates in non-cancer contexts unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The finding that Gdf15-knockout mice develop larger infarcts and that recombinant GDF15 rescues cardiomyocyte survival via PI3K-Akt1 established GDF15 as a cardioprotective cytokine with a defined survival signaling pathway.\",\n      \"evidence\": \"Gdf15-KO mice with coronary ligation, recombinant GDF15 rescue, PI3K inhibitor and dominant-negative Akt1 blockade\",\n      \"pmids\": [\"16397141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating cardiac PI3K-Akt1 activation unknown\", \"Whether cardioprotection is paracrine or autocrine not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that tumor-derived GDF15 causes cancer-associated anorexia reversible by neutralizing antibody, and that erythroid GDF15 suppresses hepatic hepcidin in β-thalassemia, revealed two major systemic endocrine functions.\",\n      \"evidence\": \"Prostate cancer xenograft models with anti-MIC-1 antibody reversal; β-thalassemia patient serum immunodepletion restoring hepcidin in primary hepatocytes\",\n      \"pmids\": [\"17982462\", \"17721544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Central receptor not identified\", \"Receptor mediating hepcidin suppression unknown\", \"Relative contribution of GDF15 vs. other erythroid factors to iron overload not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Four independent groups simultaneously identified GFRAL as the high-affinity receptor for GDF15, restricted to area postrema and NTS neurons and requiring RET as a co-receptor, resolving the two-decade-old receptor question and defining the neural circuit for appetite suppression.\",\n      \"evidence\": \"Receptor binding assays, Gfral-KO mice refractory to GDF15-induced anorexia, GFRAL monoclonal antibody blockade, ISH/IHC localization, RET co-receptor signaling studies, c-Fos neuronal activation mapping\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28953886\", \"28846099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peripheral receptor(s) mediating GFRAL-independent effects remain unidentified\", \"Downstream intracellular signaling in GFRAL+ neurons incompletely mapped\", \"Whether GFRAL has additional ligands unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Integrated stress response transcription factors ATF4/CHOP and dietary/pharmacological stressors were shown to drive GDF15 expression, and GDF15 was established as the required mediator of metformin's anorectic and weight-lowering effects in mice and humans, while conditioned taste aversion experiments revealed an aversive rather than classical satiety mechanism.\",\n      \"evidence\": \"GDF15-null mice unresponsive to metformin weight loss, two independent RCTs showing metformin increases circulating GDF15, ISR pathway analysis, GFRAL antagonist antibody, conditioned taste aversion behavioral assay\",\n      \"pmids\": [\"32694673\", \"31875646\", \"30639358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether metformin-GDF15 axis is relevant in lean individuals unknown\", \"Precise neural mechanism translating GFRAL activation to malaise not defined\", \"Tissue source hierarchy for metformin-induced GDF15 not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ARRB1 was identified as a direct interactor of pro-GDF15 required for its Golgi transport and proteolytic maturation, revealing a previously unknown step in GDF15 secretory processing.\",\n      \"evidence\": \"Co-IP of ARRB1 with pro-GDF15, Arrb1-KO mice with impaired GDF15 maturation and steatohepatitis rescued by recombinant GDF15, subcellular fractionation\",\n      \"pmids\": [\"31857195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease responsible for pro-GDF15 cleavage not identified\", \"Whether ARRB1 role is specific to GDF15 or shared with other TGF-β family members unknown\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapping the peripheral effector arm showed that GDF15-GFRAL signaling activates sympathetic outflow requiring ATGL for adipose lipolysis, and that GDF15 induces visceral malaise distinct from GLP-1 receptor agonist mechanisms.\",\n      \"evidence\": \"GFRAL antagonist antibody, chemical sympathectomy, ATGL-KO mice in cachexia models; rat behavioral paradigms with fiber photometry comparing GDF15 vs. semaglutide\",\n      \"pmids\": [\"32661391\", \"35129264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether sympathetic axis mediates GDF15's effects on muscle wasting not resolved\", \"Neural pathway from AP/NTS to sympathetic outflow not fully traced\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"AMPKβ1 was identified as a stress-responsive transcriptional inducer of hepatic GDF15 independent of ER stress/CHOP, expanding the regulatory inputs beyond the canonical ISR.\",\n      \"evidence\": \"AMPKβ1-KO and CHOP-KO mice treated with three pharmacological AMPK activators, hepatic Gdf15 expression and serum measurements\",\n      \"pmids\": [\"33337559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor downstream of AMPK that directly drives GDF15 promoter not identified\", \"Whether AMPKβ1 and ATF4/CHOP pathways converge or are fully independent in vivo unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-transcriptional control of GDF15 was revealed through CNOT6L deadenylase regulation of Gdf15 mRNA stability, and peripheral anti-inflammatory mechanisms were expanded to include AIM2 inflammasome suppression and AGE/RAGE-NF-κB inhibition in liver and kidney disease models.\",\n      \"evidence\": \"CNOT6L genetic inhibition stabilizing Gdf15 mRNA; GDF15-transgenic mice showing reduced AIM2 activation in NASH and reduced TLR4/NF-κB in diabetic nephropathy\",\n      \"pmids\": [\"35385705\", \"35504134\", \"36367498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CNOT6L regulation is tissue-specific not established\", \"Receptor mediating GDF15's peripheral anti-inflammatory effects unknown\", \"No structural basis for GDF15-mRNA deadenylase interaction\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"GDF15 was shown to signal through ALK5 (TGF-β type I receptor) in lung fibroblasts to drive α-SMA expression, and GDF15 neutralization reduced bleomycin-induced lung fibrosis, revealing a pro-fibrotic peripheral signaling axis.\",\n      \"evidence\": \"Recombinant GDF15 with ALK5 inhibitor in fibroblasts, IPF ECM proteomics, bleomycin mouse model with GDF15 neutralizing antibody\",\n      \"pmids\": [\"35993367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ALK5 is a direct GDF15 receptor or requires a co-receptor not determined\", \"Relationship between ALK5 signaling and GFRAL-independent effects in other tissues unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"GDF15 was found to counteract adaptive thermogenesis during caloric restriction through a GFRAL–β-adrenergic–skeletal muscle axis driving fatty acid oxidation and calcium futile cycling, providing a mechanism for sustained energy expenditure during weight loss beyond appetite suppression.\",\n      \"evidence\": \"GFRAL-KO mice under caloric restriction, β-blocker pharmacology, skeletal muscle fatty acid oxidation and calcium cycling assays\",\n      \"pmids\": [\"37380764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this anti-thermogenic-adaptation pathway operates in humans not tested\", \"Molecular identity of muscle calcium cycling targets downstream of β-adrenergic signaling not specified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"GDF15 was shown to reprogram macrophages toward oxidative phosphorylation and an anti-inflammatory phenotype, and adoptive transfer of GDF15-conditioned macrophages attenuated liver fibrosis, while leptin receptor signaling in NTS was found to potentiate GDF15's central metabolic effects.\",\n      \"evidence\": \"Gdf15-KO mice in CCl4/DDC fibrosis models, adoptive macrophage transfer, CyTOF immune profiling, metabolic flux analysis; combined GDF15-leptin infusion with AAV-LepR knockdown in NTS\",\n      \"pmids\": [\"37499753\", \"37433299\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating GDF15's macrophage reprogramming not identified\", \"Whether leptin-GDF15 synergy occurs in humans unknown\", \"Degree to which macrophage reprogramming vs. direct hepatocyte effects drive anti-fibrotic action not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Hepatic GFRAL-independent GDF15 signaling was mapped to SMAD3 pathway attenuation that restores AMPK activity and suppresses gluconeogenesis and fibrosis, while cardiac ISR-driven GDF15 was identified as a mediator of cardiac cachexia blockable by GDF15 antibody.\",\n      \"evidence\": \"Gdf15-KO mice with elevated pSMAD3 and gluconeogenesis rescued by SMAD3 inhibitor; PPP1R15A-KO dilated cardiomyopathy model with GDF15 blocking antibody preventing cachexia\",\n      \"pmids\": [\"38176644\", \"39312445\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Peripheral hepatic receptor for GDF15 that mediates SMAD3 attenuation not identified\", \"Whether cardiac GDF15 blockade is therapeutically viable without compromising stress-protective functions unknown\", \"Structural basis for GDF15-SMAD3 pathway interaction not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of peripheral receptor(s) mediating GDF15's GFRAL-independent effects on macrophages, hepatocytes, and fibroblasts remains the central unresolved question; proposed interactors (ErbB2, CD48, ALK5) each derive from single laboratories and await independent validation and structural characterization.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No consensus peripheral receptor identified\", \"No crystal structure of full-length GDF15-GFRAL-RET ternary complex\", \"Therapeutic window between beneficial metabolic effects and detrimental cachexia/aversion not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 4, 8, 9, 16, 30]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 32, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 4, 5, 7, 8, 14, 16]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 8, 9, 16, 30, 33]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 17, 22, 32]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [6, 7, 12, 14, 20, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GFRAL\",\n      \"RET\",\n      \"ARRB1\",\n      \"TP53\",\n      \"ATF4\",\n      \"DDIT3\",\n      \"PRKAB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}